{"id":"penpulimab","rwe":[{"pmid":"41860583","year":"2026","title":"Cost-effectiveness of first-line immune checkpoint inhibitor therapies, alone or combined with targeted agents, for unresectable hepatocellular carcinoma in China: an economic evaluation using network meta-analysis.","finding":"","journal":"Immunotherapy","studyType":"Clinical Study"},{"pmid":"41854985","year":"2026","title":"Cost-Effectiveness Analysis of Anlotinib Plus Penpulimab Versus Sorafenib in the First-Line Treatment of Unresectable Hepatocellular Carcinoma in China.","finding":"","journal":"Clinical drug investigation","studyType":"Clinical Study"},{"pmid":"41816591","year":"2026","title":"Anlotinib and penpulimab in advanced hepatocellular carcinoma: a new contender emerges.","finding":"","journal":"Journal of gastrointestinal oncology","studyType":"Clinical Study"},{"pmid":"41804358","year":"2026","title":"Immune checkpoint inhibitor-based first-line therapies for advanced or unresectable hepatocellular carcinoma: a network meta-analysis and cost-effectiveness analysis.","finding":"","journal":"Therapeutic advances in medical oncology","studyType":"Clinical Study"},{"pmid":"41694404","year":"2026","title":"Efficacy and safety of first-line immunotherapy and targeted therapy in advanced HCC: a network meta-analysis with subgroup analysis based on HBV and HCV infection.","finding":"","journal":"Frontiers in immunology","studyType":"Clinical Study"}],"_fda":{"id":"3392cd59-0d45-e081-e063-6394a90a0353","set_id":"830004e8-31af-4cc6-ab16-e870cab1c5ca","openfda":{"unii":["IBS1BZ4E4I"],"route":["INTRAVENOUS"],"rxcui":["2712652"],"spl_id":["3392cd59-0d45-e081-e063-6394a90a0353"],"brand_name":["Penpulimab kcqx"],"spl_set_id":["830004e8-31af-4cc6-ab16-e870cab1c5ca"],"package_ndc":["83654-105-01"],"product_ndc":["83654-105"],"generic_name":["PENPULIMAB"],"product_type":["HUMAN PRESCRIPTION DRUG"],"substance_name":["PENPULIMAB"],"manufacturer_name":["Akeso Biopharma, Co., Ltd"],"application_number":["BLA761258"],"is_original_packager":[true]},"version":"1","description":["11 DESCRIPTION Penpulimab-kcqx is a programmed death receptor-1 (PD 1)-blocking antibody. Penpulimab-kcqx is a humanized monoclonal IgG1 antibody with an approximate molecular weight of 150 kDa. Penpulimab-kcqx is produced in Chinese hamster ovary (CHO) cells. Penpulimab-kcqx injection is a sterile, preservative-free, clear to slightly opalescent, colorless to yellowish solution for intravenous infusion after dilution. Each vial contains 100 mg of penpulimab-kcqx in 10 mL solution. Each mL of solution contains: penpulimab-kcqx 10 mg, acetic acid (0.09 mg), polysorbate 80 (0.2 mg), sodium acetate (2.52 mg), sorbitol (45 mg), and Water for Injection, USP. The pH of the solution is 5.8."],"how_supplied":["16 HOW SUPPLIED/STORAGE AND HANDLING How Supplied Penpulimab-kcqx injection is a sterile, preservative-free, clear to slightly opalescent, colorless to yellowish solution supplied as: Carton containing one 100 mg/10 mL (10 mg/mL) single-dose vial NDC 83654-105-01 Storage and Handling Store refrigerated at 2°C to 8°C (36°F to 46°F) in the original carton to protect from light. Do not shake. Do not freeze."],"spl_medguide":["MEDICATION GUIDE PENPULIMAB-KCQX (pen pul i mab kcqx) injection What is the most important information I should know about penpulimab-kcqx? Penpulimab-kcqx is a medicine that may treat non-keratinizing nasopharyngeal cancer by working with your immune system. Penpulimab-kcqx can cause your immune system to attack normal organs and tissues in any area of your body and can affect the way they work. These problems can sometimes become severe or life-threatening and can lead to death. You can have more than one of these problems at the same time. These problems may happen anytime during treatment or even after your treatment has ended. Call or see your healthcare provider right away if you develop any new or worsening signs or symptoms, including: Lung problems cough shortness of breath chest pain Intestinal problems diarrhea (loose stools) or more frequent bowel movements than usual stools that are black, tarry, sticky, or have blood or mucus severe stomach-area (abdomen) pain or tenderness Liver problems yellowing of your skin or the whites of your eyes dark urine (tea colored) severe nausea or vomiting bleeding or bruising more easily than normal pain on the right side of your stomach-area (abdomen) Hormone gland problems headaches that will not go away or unusual headaches urinating more often than usual eye sensitivity to light hair loss eye problems feeling cold rapid heartbeat constipation increased sweating your voice gets deeper extreme tiredness dizziness or fainting weight gain or weight loss changes in mood or behavior, such as decreased sex drive, irritability, or forgetfulness feeling more hungry or thirsty than usual Kidney problems decrease in your amount of urine swelling of your ankles blood in your urine loss of appetite Skin problems rash painful sores or ulcers in your mouth or nose, throat, or genital area itching fever or flu-like symptoms skin blistering or peeling swollen lymph nodes Problems can also happen in other organs and tissues. These are not all of the signs and symptoms of immune system problems that can happen with penpulimab-kcqx. Call or see your healthcare provider right away for any new or worsening signs or symptoms, which may include: chest pain, irregular heartbeat, shortness of breath, swelling of ankles confusion, sleepiness, memory problems, changes in mood or behavior, stiff neck, balance problems, tingling or numbness of the arms or legs double vision, blurry vision, sensitivity to light, eye pain, changes in eyesight persistent or severe muscle pain or weakness, muscle cramps low red blood cells, bruising Infusion reactions that can sometimes be severe or life-threatening . Signs and symptoms of infusion reactions may include: chills or shaking dizziness itching or rash feeling like passing out flushing fever shortness of breath or wheezing back pain Rejection of a transplanted organ or tissue. Your healthcare provider should tell you what signs and symptoms you should report and monitor you depending on the type of organ or tissue transplant that you have had. Complications, including graft-versus-host-disease (GVHD), in people who have received a bone marrow (stem cell) transplant that uses donor stem cells (allogeneic). These complications can be serious and can lead to death. These complications may happen if you underwent transplantation either before or after being treated with penpulimab-kcqx. Your healthcare provider will monitor you for these complications. Getting medical treatment right away may help keep these problems from becoming more serious. Your healthcare provider will check for these problems during treatment with penpulimab-kcqx. Your healthcare provider may treat you with corticosteroid or hormone replacement medicines. Your healthcare provider may also need to delay or completely stop treatment with penpulimab-kcqx if you have severe side effects. What is penpulimab-kcqx? Penpulimab-kcqx is a prescription medicine used to treat adults with a kind of cancer called non-keratinizing nasopharyngeal carcinoma (NPC). Penpulimab-kcqx may be used in combination with either the chemotherapy medicines cisplatin or carboplatin and gemcitabine, as your first treatment when your non-keratinizing NPC has returned (recurrent) or has spread to other parts of your body (metastatic). Penpulimab-kcqx may be used alone to treat your non-keratinizing NPC when it: has spread (metastatic), and you received chemotherapy that contains platinum and at least 1 other type of treatment, and it did not work or is no longer working. It is not known if penpulimab-kcqx is safe and effective in children. Before receiving penpulimab-kcqx, tell your healthcare provider about all of your medical conditions, including if you: have immune system problems such as Crohn’s disease, ulcerative colitis, or lupus have received an organ transplant, including corneal transplant have received or plan to receive a stem cell transplant that uses donor stem cells (allogeneic) have received radiation treatment to your chest area have a condition that affects your nervous system, such as myasthenia gravis or Guillain-Barré syndrome are pregnant or plan to become pregnant. Penpulimab-kcqx can harm your unborn baby. Females who are able to become pregnant: Your healthcare provider will give you a pregnancy test before you start treatment with penpulimab-kcqx. You should use an effective method of birth control during your treatment and for 4 months after your last dose of penpulimab-kcqx. Talk to your healthcare provider about birth control methods that you can use during this time. Tell your healthcare provider right away if you become pregnant or think you may be pregnant during treatment with penpulimab-kcqx. are breastfeeding or plan to breastfeed. It is not known if penpulimab-kcqx passes into your breast milk. Do not breastfeed during treatment with penpulimab-kcqx and for 4 months after your last dose of penpulimab-kcqx. Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. How will I receive penpulimab-kcqx? Your healthcare provider will give you penpulimab-kcqx into your vein through an intravenous (IV) line over 60 minutes. Penpulimab-kcqx is usually given every 2 or 3 weeks. Your healthcare provider will decide how many treatments you need. Your healthcare provider will test your blood to check you for certain side effects. If you miss any appointments, call your healthcare provider as soon as possible to reschedule your appointment. What are the possible side effects of penpulimab-kcqx? Penpulimab-kcqx can cause serious side effects. See “What is the most important information I should know about penpulimab-kcqx?” The most common side effects of penpulimab-kcqx when used in combination with either cisplatin or carboplatin and gemcitabine include: nausea decreased appetite feeling tired vomiting decreased weight rash low thyroid hormone levels cough fever constipation COVID-19 infection The most common side effects of penpulimab-kcqx when used alone include low red blood cell count (anemia) and low thyroid hormone levels. These are not all the possible side effects of penpulimab-kcqx. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088. General information about the safe and effective use of penpulimab-kcqx. Medicines are sometimes prescribed for purposes other than those listed in a Medication Guide. You can ask your pharmacist or healthcare provider for information about penpulimab-kcqx that is written for healthcare professionals. What are the ingredients in penpulimab-kcqx? Active ingredient: penpulimab-kcqx Inactive ingredients: acetic acid, polysorbate 80, sodium acetate, sorbitol, and Water for Injection. Manufactured by: Akeso Biopharma Co., Ltd., 6 Shennong Road, Torch Development Zone, Zhongshan, Guangdong 528437, China U.S. License No. xxxx For more information, call 833-662-5376 or go to https://www.akesobio.com/en/. This Medication Guide has been approved by the U.S. Food and Drug Administration. Issued: April/2025"],"effective_time":"20250424","clinical_studies":["14 CLINICAL STUDIES 14.1 First-line Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma The efficacy of penpulimab-kcqx in combination with either cisplatin or carboplatin and gemcitabine was evaluated in Study AK105-304 (NCT04974398), a randomized, double-blind, multi-center trial. The trial included a total of 291 patients with recurrent or metastatic nasopharyngeal carcinoma (NPC). Eligible patients were required to have recurrent NPC with local-regional recurrence and/or distant metastasis occurring ≥ 6 months after completion of curative intent treatment or to have primary metastatic NPC not suitable for local therapy at the time of diagnosis. Patients with autoimmune disease, other than stable hypothyroidism or Type I diabetes, and patients who required systemic immunosuppression were ineligible. Patients were randomized (1:1) to receive either: Penpulimab-kcqx in combination with either cisplatin or carboplatin and gemcitabine, every 3 weeks, for up to 6 cycles, followed by single-agent penpulimab-kcqx every 3 weeks until disease progression or unacceptable toxicity or a maximum of 24 months. Placebo in combination with either cisplatin or carboplatin and gemcitabine, every 3 weeks for up to 6 cycles, followed by single-agent placebo every 3 weeks until disease progression or unacceptable toxicity or a maximum of 24 months. All study medications were administered intravenously. Randomization was stratified by stage of disease (primary metastatic vs. recurrent), Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) (0 vs. 1), and liver metastasis (present vs. absent). Patients randomized to placebo were eligible to receive open-label single-agent penpulimab-kcqx (200 mg every 3 weeks) after radiographic disease progression confirmed by blinded independent central review (BICR). Tumor assessments were performed every 6 weeks for the first 12 months and every 9 weeks thereafter. The major efficacy outcome measure was BICR-assessed progression-free survival (PFS) according to RECIST v1.1. The key secondary efficacy outcome measure was overall survival (OS). The study population characteristics were: median age of 51 years (range: 23 to 75), 82% male, 98% Asian, 2.1% White; 1.4% Hispanic or Latino; and 36% ECOG PS of 0. At study entry, 80% of patients had metastatic disease. Histological subtypes of NPC included 96% non-keratinizing, 0.7% keratinizing squamous cell carcinoma, and 3.4% did not have the subtype identified. In total, 98% received cisplatin and 2.4% received carboplatin. Efficacy results of the analysis of PFS are summarized in Table 7 and Figure 1 below. The trial demonstrated statistically significant improvements in BICR-assessed PFS for patients randomized to penpulimab-kcqx in combination with either cisplatin or carboplatin and gemcitabine compared to placebo with either cisplatin or carboplatin and gemcitabine. OS results were not mature with 70% of pre-specified OS events observed in the overall population. Table 7 Efficacy Results in AK105-304 Endpoint Penpulimab-kcqx cisplatin or carboplatin and gemcitabine N=144 Placebo cisplatin or carboplatin and gemcitabine N=147 BICR-assessed Progression-free Survival Number of Events n (%) 80 (56) 109 (74) Median, months (95% CI) 9.6 (7.1, 12.5) 7.0 (6.9, 7.3) Hazard Ratio (95% CI) † 0.45 (0.33, 0.62) p-value ‡ <0.0001 † Based on a stratified Cox proportional hazard model. ‡ Two-sided p-value, based on the stratified log-rank test, as compared with an alpha boundary of 0.030. Figure 1 Kaplan-Meier Curves of PFS for AK105-304 Figure 1 Kaplan-Meier Curves of PFS for AK105-304 14.2 Recurrent Metastatic Non-Keratinizing Nasopharyngeal Carcinoma The efficacy of single-agent penpulimab-kcqx was evaluated in Study AK105-202 (NCT03866967), an open-label, multicenter, single-arm trial conducted in a single country. The trial included a total of 125 patients with unresectable or metastatic non-keratinizing nasopharyngeal carcinoma (NPC) and who had disease progression after platinum-based chemotherapy and at least one other line of therapy. Patients with a history of autoimmune disease or a medical condition that required immunosuppression were ineligible. Patients received single-agent penpulimab-kcqx 200 mg intravenously every 2 weeks until disease progression or unacceptable toxicity or a maximum of 24 months. Tumor assessments were performed every 8 weeks in the first year and every 12 weeks thereafter. The major efficacy outcome measures were objective response rate (ORR) and duration of response (DOR) according to RECIST v1.1 as assessed by an Independent Radiology Review Committee (IRRC). The median age was 50 years (range: 21 to 66 years); 76% were male; 100% were Asian; none were Hispanic or Latino; and Eastern Cooperative Oncology Group (ECOG) performance score (PS) was 0 (31%) or 1 (69%). In total, 10% of patients had tumors with PD-L1 TPS <1%, 50% of patients had tumors with PD-L1 TPS 1-49%, 37% of patients had tumors with PD-L1 TPS ≥50%, and 2.4% of patients had tumors with missing PD-L1 expression levels. Sixty-three percent of patients had received 2 prior lines of chemotherapy, and 37% of patients had received 3 or more prior lines of chemotherapy. Ninety-two percent of patients had received prior radiotherapy. Efficacy results are summarized in Table 8. Table 8 Efficacy Results in Study AK105-202 Efficacy Parameter Penpulimab-kcqx ( N=125) Objective Response Rate, % (95% CI) 28 (20, 37) Complete response rate, % 0.8 Partial response rate, % 27 Duration of Response (DOR) N=35 Median a , months (95% CI) NR (9.2, NE) Patients with DOR ≥ 12 months (%) b 46 a Estimate using Kaplan-Meier method. b Based on the observed DOR data. NR = not reached; NE = not estimable"],"pharmacokinetics":["12.3 Pharmacokinetics Penpulimab-kcqx exposure increased dose proportionally over the dose range of 1 to 10 mg/kg (0.35 to 3.5 times the approved recommended dosage in a 70 kg patient) after the first dose. The mean accumulation ratio was 1.5 for maximum concentration (C max ) and 2.1 for area under the concentration curve (AUC) following multiple doses of 200 mg every 3 weeks. Steady-state concentrations of penpulimab-kcqx were reached by Week 15, with mean (CV%) steady-state trough and peak concentrations of 30 μg/mL (38%) and 88 μg/mL (21%), respectively. Distribution The mean (CV%) volume of distribution was 10 L (44%). Elimination The mean (CV%) clearance was 0.2 L/day (33%) and the mean (CV%) terminal half-life was 32 days (44%). Metabolism Penpulimab-kcqx is expected to be metabolized into small peptides by catabolic pathways. Specific Populations No clinically significant differences in the pharmacokinetics of penpulimab-kcqx were observed based on body weight (32 to 113 kg), age (18 to 91 years), sex, race (White and Asian), serum albumin (22 to 54.5 g/L), baseline LDH (111 to 4,450 IU/L), baseline C-reactive protein (0 to 328 mg/L), baseline ECOG score (0 and 1), immunogenicity status, tumor type (NPC and other tumors), co-administration (with chemotherapy), mild or moderate renal impairment (creatinine clearance [CLcr] ≥ 30 mL/min), mild (total bilirubin ≤ ULN and AST > ULN or total bilirubin > 1 to 1.5 times ULN and any AST) or moderate hepatic impairment (total bilirubin > 1.5 to 3 times ULN and any AST). The effect of severe hepatic (total bilirubin > 3 times ULN and any AST) or renal impairment (CLcr < 30 mL/min) on the pharmacokinetics of penpulimab-kcqx is unknown."],"adverse_reactions":["6 ADVERSE REACTIONS The following adverse reactions are described in other sections of the labeling: Severe and Fatal Immune-Mediated Adverse Reactions [see Warnings and Precautions (5.1) ] Infusion-Related Reactions[see Warnings and Precautions (5.2) ] Complications of Allogeneic HSCT [see Warnings and Precautions (5.3) ] Penpulimab-kcqx in combination with either cisplatin or carboplatin and gemcitabine : The most common adverse reactions (≥20%) were nausea, vomiting, hypothyroidism, constipation, decreased appetite, decreased weight, cough, COVID-19 infection, fatigue, rash, and pyrexia. (6.1) Penpulimab-kcqx as a single agent : The most common adverse reactions (≥20%) were anemia and hypothyroidism. (6.1) To report SUSPECTED ADVERSE REACTIONS, contact Akeso Biopharma Co., Ltd. at toll-free phone 833-662-5376 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. 6.1 Clinical Trials Experience Because clinical trials are conducted under varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to those observed in the clinical trials of another drug and may not reflect the rates observed in practice. The data described in the WARNINGS AND PRECAUTIONS reflect exposure to penpulimab-kcqx in 146 patients in Study AK105-304 [see Clinical Studies (14.1) ] . Patients received 6 cycles every 3 weeks of intravenous penpulimab-kcqx 200 mg in combination with either cisplatin 80 mg/m 2 or carboplatin AUC 5 and gemcitabine 1000 mg/m 2 followed by single-agent penpulimab-kcqx 200 mg every 3 weeks until disease progression or a maximum of 24 months. Among the 146 patients who received penpulimab-kcqx in combination with either cisplatin or carboplatin and gemcitabine, 71% were exposed for 6 months or longer and 38% were exposed for greater than one year. In this safety population, the most common (≥ 20%) adverse reactions were nausea (58%), vomiting (55%), hypothyroidism (45%), constipation (41%), decreased appetite (36%), decreased weight (26%), cough (25%), COVID-19 infection (25%), fatigue (25%), rash (24%) and pyrexia (21%). The most common Grade 3 to 4 laboratory abnormalities (≥ 2%) were decreased lymphocytes (70%), decreased neutrophils (61%), decreased white blood cells (58%), decreased hemoglobin (49%), decreased platelets (33%), decreased potassium (14%), increased lipase (11%), increased ALT (8%), decreased sodium (7%), increased AST (6%), increased triglycerides (4.3%), decreased magnesium (4.2%), decreased CPK (4.1%), increased amylase (2.9%), increased potassium (2.8%), increased cholesterol (2.2%), increased calcium (2.1%) and increased blood bilirubin (2.1%). The data described in the WARNINGS AND PRECAUTIONS also reflect exposure to single-agent intravenous penpulimab-kcqx 200 mg every 2 weeks until disease progression or a maximum of 24 months in 372 patients in studies: AK105-101 [NCT03352531], AK-105-201 [NCT03722147], AK105-202 [see Clinical Studies (14.2)] , AK105-204 [NCT 04172506]. Among the 372 patients who received single-agent penpulimab-kcqx, 49% were exposed for 6 months or longer and 34% were exposed for at least one year. In this safety population, the most common (≥20%) adverse reactions were anemia (25%) and hypothyroidism (23%). The most common Grade 3 to 4 laboratory abnormalities (≥ 2%) were decreased lymphocytes (11%), increased GGT (9%), decreased phosphate (6%), decreased sodium (4.7%), increased aspartate aminotransferase (4.4%), increased alkaline phosphatase (4%), decreased hemoglobin (3.6%), increased bilirubin (2.7%), increased glucose (3%), increased triglycerides (2.8%), increased alanine aminotransferase (2.5%), increased magnesium (3.3%), and decreased platelets (2.5%). First line Recurrent or Metastatic Nasopharyngeal Carcinoma Study AK105-304 The safety of penpulimab-kcqx in combination with either cisplatin or carboplatin and gemcitabine was evaluated in Study AK105-304 [see Clinical Studies (14.1) ] . Patients received intravenous placebo or penpulimab-kcqx 200 mg every 3 weeks in combination with 6 cycles of either cisplatin 80 mg/m 2 or carboplatin AUC 5 and gemcitabine 1000 mg/m 2 every 3 weeks followed by placebo or penpulimab-kcqx 200 mg intravenously every 3 weeks until unacceptable toxicity, disease progression or a maximum of 24 months. Among patients who received penpulimab-kcqx, 71% were exposed for 6 months or longer and 38% were exposed for greater than one year. The median age of patients who received penpulimab-kcqx was 51 years (23 to 75 years); 82% were male; 97% were Asian, 3.4% were White; 2.1% were Hispanic or Latino, baseline Eastern Cooperative Oncology Group (ECOG) performance score was 0 (36%) or 1 (64%). Of the 146 patients, 69% of patients had received at least one prior systemic therapy and 100% of patients had received prior radiation therapy. Serious adverse reactions occurred in 51% of patients. The most frequent serious adverse reactions (≥2%) were thrombocytopenia (19%), decreased neutrophils (14%), decreased white blood cells (12%), anemia (8%), myelosuppression (3.4%), decreased sodium (2.7%), pneumonia (2.1%), and nausea (2.1%). Of the patients who received penpulimab-kcqx in combination with either cisplatin or carboplatin and gemcitabine, there was one fatal adverse reaction (0.7%) due to syndrome of inappropriate antidiuretic hormone secretion (SIADH). Permanent discontinuation of penpulimab-kcqx due to an adverse reaction occurred in 3.4% of patients. Adverse reactions which resulted in permanent discontinuation of penpulimab-kcqx were acute myocardial infarction, acute kidney injury, brain edema, diabetic ketoacidosis, increased potassium, increased lipase, and thrombocytopenia (0.7% each). Dose interruptions of penpulimab-kcqx due to an adverse reaction occurred in 64% of patients. Adverse reactions which required dose interruption in ≥ 2% of patients included COVID-19 (16%), anemia (16%), thrombocytopenia (14%), decreased white blood cells (14%), decreased neutrophils (10%), pneumonia (10%), increased alanine aminotransferase (3.4%), increased aspartate aminotransferase (2.7%), decreased sodium (2.7%), increased blood creatinine (2.7%), pyrexia (2.1%), and upper respiratory tract infection (2.1%). Table 3 summarizes the adverse reactions in Study AK105-304. Table 3 Adverse Reactions (≥ 10%) in Patients with Recurrent or Metastatic NPC Who Received Penpulimab-kcqx in Combination with Either Cisplatin or Carboplatin and Gemcitabine in Study AK105-304 Adverse Reaction Penpulimab-kcqx Cisplatin or Carboplatin and Gemcitabine N = 146 Placebo Cisplatin or Carboplatin and Gemcitabine N = 142 All Grades 1 (%) Grade 3 or 4 1 (%) All Grades 1 (%) Grade 3 or 4 1 (%) Gastrointestinal disorders Nausea 58 2.1 64 0 Vomiting 2 55 1.4 54 1.4 Constipation 41 0 44 0 Abdominal distension 12 0 6 0 Endocrine disorders Hypothyroidism 3 45 0 27 0 Metabolism and nutrition disorders Decreased appetite 36 0 39 0 Investigations Weight decreased 26 1.4 16 0 Respiratory, thoracic and mediastinal disorders Cough 4 25 0 16 0 Infections and infestations COVID-19 25 0 17 0.7 General disorders and administration site conditions Fatigue 5 25 1.4 22 0 Pyrexia 21 0 20 0.7 Malaise 10 0 8 0 Skin and subcutaneous tissue disorders Rash 6 24 1.4 20 0 Pruritus 11 0 11 0 Nervous system disorders Headache 15 0.7 10 0.7 Dizziness 7 14 0 15 0.7 Renal and urinary disorders Proteinuria 14 0 13 0 Acute kidney injury 8 13 1.4 4.9 0 Musculoskeletal and connective tissue disorders Musculoskeletal pain 9 14 0.7 24 0 Psychiatric disorders Insomnia 12 0 10 0 1 Graded per NCI CTCAE v5.0 2 Includes retching 3 Includes blood thyroid stimulating hormone increased, secondary hypothyroidism 4 Includes productive cough, upper-airway cough syndrome 5 Includes asthenia 6 Includes dermatitis, dermatitis acneiform, drug eruption, eczema, rash maculo-papular, rash papular, rash pustular 7 Includes vertigo 8 Includes acute kidney injury, creatinine renal clearance decreased, glomerular filtration rate decreased, renal failure, renal impairment 9 Includes arthralgia, arthritis, back pain, bone pain, musculoskeletal chest pain, musculoskeletal discomfort, myalgia, neck pain, pain in extremity, spinal pain Table 4 summarizes the laboratory abnormalities in AK105-304. Table 4 Select Laboratory Abnormalities (≥20%) That Worsened from Baseline in Patients with Recurrent or Metastatic NPC Who Received Penpulimab-kcqx in Combination with Either Cisplatin or Carboplatin and Gemcitabine in Study AK105-304 Laboratory Abnormality Penpulimab-kcqx Cisplatin or Carboplatin /Gemcitabine 2 Placebo Cisplatin or Carboplatin /Gemcitabine 3 All Grades 1 (%) Grade 3 or 4 1 (%) All Grades 1 (%) Grade 3 or 4 1 (%) Hematology White blood cell decreased 99 58 97 58 Hemoglobin decreased 98 49 97 47 Lymphocytes decreased 93 70 89 58 Neutrophils decreased 92 61 95 65 Chemistry Magnesium decreased 69 4.2 58 3.6 Sodium decreased 62 7 58 7 Triglycerides increased 58 4.3 53 4.3 Aspartate aminotransferase increased 52 6 37 2.9 Cholesterol increased 49 2.2 46 0.7 Creatinine increased 48 1.4 39 0.7 Albumin decreased 47 0 44 1.4 Potassium decreased 45 14 31 3.6 Alanine aminotransferase increased 42 8 37 2.1 GGT increased 36 1.4 33 0.7 Alkaline phosphatase increased 32 0.7 30 0 Lipase increased 28 11 23 3.9 Chloride decreased 25 1.4 11 0 Serum amylase increased 23 2.9 17 0.7 Glucose decreased 22 1.4 20 0.7 Lipids increased 21 1.4 20 0.7 1 Toxicity graded according to NCI CTCAE v5.0. 2 The denominator used to calculate the rate varied from 102 to 146 based on the number of patients with a baseline value and at least one post-treatment value. 3 The denominator used to calculate the rate varied from 103 to 142 based on the number of patients with a baseline value and at least one post-treatment value. Recurrent Metastatic Non-Keratinizing Nasopharyngeal Carcinoma Study AK105-202 The safety of penpulimab-kcqx as a single agent was evaluated in Study AK105-202 [see Clinical Studies (14.2) ]. Eligible patients had metastatic non-keratinizing NPC and had received prior platinum-based chemotherapy and at least one other line of therapy or had disease progression within 6 months of completion of platinum-based chemotherapy administered as neoadjuvant, adjuvant, or definitive chemoradiation treatment. Patients received penpulimab-kcqx 200 mg intravenously every 2 weeks until unacceptable toxicity, disease progression, or a maximum of 24 months. Among patients who received penpulimab-kcqx, 45% were exposed for 6 months or longer and 30% for exposed for greater than one year. The median age of patients who received penpulimab-kcqx was 50 years (20 to 66 years); 76% were male; 100% were Asian, 100% had recurrent disease; baseline Eastern Cooperative Oncology Group (ECOG) performance score was 0 (31%) or 1 (69%). All patients had received at least one prior systemic therapy and prior radiation. Serious adverse reactions occurred in 22% of patients. Serious adverse reactions in ≥1% were pneumonia (3.8%), pneumonitis (1.5%), respiratory failure (1.5%), rash (1.5%). Fatal adverse reactions occurred in 1% of patients treated with penpulimab-kcqx, including a case each of pneumonitis, septic shock, colitis, and hepatitis. Permanent discontinuation of penpulimab-kcqx due to an adverse reaction occurred in 3.8% of patients. Adverse reactions which resulted in permanent discontinuation of penpulimab-kcqx in ≥1% were rash, hepatitis, herpes zoster, spinal cord compression and pleural effusion (0.8% each). Dose interruptions of penpulimab-kcqx due to an adverse reaction occurred in 25% of patients. Adverse reactions which required dose interruption in ≥ 1% of patients included hepatitis (6.2%), anemia (3.1%), pneumonia (3.1%), hypothyroidism (3.1%), rash (1.5%) and white blood cells decreased (1.5%). Table 5 summarizes the adverse reactions in AK105-202. Table 5 Adverse Reactions (≥ 10%) in Patients with Recurrent Metastatic Non-Keratinizing NPC Who Received Penpulimab-kcqx in Study AK105-202 Adverse Reaction Penpulimab-kcqx N = 130 All Grades 1 (%) Grade 3 or 4 1 (%) Endocrine disorders Hypothyroidism 2 39 0 Musculoskeletal and connective tissue disorders Musculoskeletal pain 3 25 0.8 Investigations Weight decreased 19 1.5 General disorders and administration site conditions Pyrexia 15 0 Infections and infestations Upper respiratory tract infection 13 0.8 Respiratory, thoracic and mediastinal disorders Cough 4 11 0 Skin and subcutaneous tissue disorders Rash 5 11 2.3 1 Graded per NCI CTCAE v5.0 2 Includes blood thyroid stimulating hormone increased 3 Includes arthralgia, back pain, bone pain, musculoskeletal chest pain, neck pain, non-cardiac chest pain, pain in extremity 4 Includes productive cough 5 Includes dermatitis acneiform, eczema, pemphigoid Table 6 summarizes the laboratory abnormalities in AK105-202. Table 6 Select Laboratory Abnormalities (≥20%) Worsening from Baseline in Patients with Recurrent Metastatic Non-Keratinizing NPC Who Received Penpulimab-kcqx in Study AK105-202 Laboratory Abnormality Penpulimab-kcqx All Grades 1 (%) 2 Grades 3 or 4 (%) Chemistry Creatinine increased 81 0 Phosphate decreased 47 8 Sodium decreased 46 6 Albumin decreased 45 0 Triglycerides increased 38 3.1 Alkaline phosphatase increased 35 5 Aspartate aminotransferase increased 33 3.9 GGT increased 34 8 Glucose increased 34 0 Magnesium decreased 28 0.8 Activated partial thromboplastin time prolonged 22 0 Alanine aminotransferase increased 20 3.9 Hematology Lymphocytes decreased 43 16 Hemoglobin decreased 36 4.7 1 Toxicity graded according to NCI CTCAE v5.0. 2 Each test incidence is based on the number of patients who had both baseline and at least one on-study laboratory measurement available: penpulimab-kcqx (range of the patient number: 128 to130)."],"contraindications":["4 CONTRAINDICATIONS None. None.(4)"],"spl_medguide_table":["<table border=\"0\" width=\"100%\"><tbody><tr><td colspan=\"4\" styleCode=\"Botrule\"><paragraph><content styleCode=\"bold\">MEDICATION GUIDE</content></paragraph><paragraph><content styleCode=\"bold\">PENPULIMAB-KCQX (pen pul i mab kcqx)</content></paragraph><content styleCode=\"bold\">injection</content></td></tr><tr><td colspan=\"4\"><paragraph><content styleCode=\"bold\">What is the most important information I should know about penpulimab-kcqx?</content></paragraph><paragraph>Penpulimab-kcqx is a medicine that may treat non-keratinizing nasopharyngeal cancer by working with your immune system. Penpulimab-kcqx can cause your immune system to attack normal organs and tissues in any area of your body and can affect the way they work. These problems can sometimes become severe or life-threatening and can lead to death. You can have more than one of these problems at the same time. These problems may happen anytime during treatment or even after your treatment has ended.</paragraph><paragraph><content styleCode=\"bold\">Call or see your healthcare provider right away if you develop any new or worsening signs or symptoms, including:</content></paragraph><paragraph><content styleCode=\"bold\">Lung problems</content></paragraph></td></tr><tr><td><list listType=\"unordered\"><item>cough</item></list></td><td><list listType=\"unordered\"><item>shortness of breath</item></list></td><td colspan=\"2\"><list listType=\"unordered\"><item>chest pain</item></list></td></tr><tr><td colspan=\"4\"><paragraph><content styleCode=\"bold\">Intestinal problems</content></paragraph><list listType=\"unordered\"><item>diarrhea (loose stools) or more frequent bowel movements than usual</item><item>stools that are black, tarry, sticky, or have blood or mucus</item><item>severe stomach-area (abdomen) pain or tenderness</item></list><paragraph/><paragraph><content styleCode=\"bold\">Liver problems</content></paragraph></td></tr><tr><td colspan=\"2\"><list listType=\"unordered\"><item>yellowing of your skin or the whites of your eyes</item></list></td><td colspan=\"2\"><list listType=\"unordered\"><item>dark urine (tea colored)</item></list></td></tr><tr><td colspan=\"2\"><list listType=\"unordered\"><item>severe nausea or vomiting</item></list></td><td colspan=\"2\"><list listType=\"unordered\"><item>bleeding or bruising more easily than normal</item></list></td></tr><tr><td colspan=\"4\"><list listType=\"unordered\"><item>pain on the right side of your stomach-area (abdomen)</item></list></td></tr><tr><td colspan=\"4\"><paragraph><content styleCode=\"bold\">Hormone gland problems</content></paragraph></td></tr><tr><td colspan=\"2\"><list listType=\"unordered\"><item>headaches that will not go away or unusual headaches</item></list></td><td colspan=\"2\"><list listType=\"unordered\"><item>urinating more often than usual</item></list></td></tr><tr><td colspan=\"2\"><list listType=\"unordered\"><item>eye sensitivity to light</item></list></td><td colspan=\"2\"><list listType=\"unordered\"><item>hair loss</item></list></td></tr><tr><td colspan=\"2\"><list listType=\"unordered\"><item>eye problems</item></list></td><td colspan=\"2\"><list listType=\"unordered\"><item>feeling cold</item></list></td></tr><tr><td colspan=\"2\"><list listType=\"unordered\"><item>rapid heartbeat</item></list></td><td colspan=\"2\"><list listType=\"unordered\"><item>constipation</item></list></td></tr><tr><td colspan=\"2\"><list listType=\"unordered\"><item>increased sweating</item></list></td><td colspan=\"2\"><list listType=\"unordered\"><item>your voice gets deeper</item></list></td></tr><tr><td colspan=\"2\"><list listType=\"unordered\"><item>extreme tiredness</item></list></td><td colspan=\"2\"><list listType=\"unordered\"><item>dizziness or fainting</item></list></td></tr><tr><td colspan=\"2\"><list listType=\"unordered\"><item>weight gain or weight loss</item></list></td><td colspan=\"2\"><list listType=\"unordered\"><item>changes in mood or behavior, such as decreased sex drive, irritability, or forgetfulness</item></list></td></tr><tr><td colspan=\"4\"><list listType=\"unordered\"><item>feeling more hungry or thirsty than usual</item></list></td></tr><tr><td colspan=\"4\"><paragraph><content styleCode=\"bold\">Kidney problems</content></paragraph></td></tr><tr><td colspan=\"2\"><list listType=\"unordered\"><item>decrease in your amount of urine</item></list></td><td colspan=\"2\"><list listType=\"unordered\"><item>swelling of your ankles</item></list></td></tr><tr><td colspan=\"2\"><list listType=\"unordered\"><item>blood in your urine</item></list></td><td colspan=\"2\"><list listType=\"unordered\"><item>loss of appetite</item></list></td></tr><tr><td colspan=\"4\"><paragraph><content styleCode=\"bold\">Skin problems</content></paragraph></td></tr><tr><td colspan=\"2\"><list listType=\"unordered\"><item>rash</item></list></td><td colspan=\"2\"><list listType=\"unordered\"><item>painful sores or ulcers in your mouth or nose, throat, or genital area</item></list></td></tr><tr><td colspan=\"2\"><list listType=\"unordered\"><item>itching</item></list></td><td colspan=\"2\"><list listType=\"unordered\"><item>fever or flu-like symptoms</item></list></td></tr><tr><td colspan=\"2\"><list listType=\"unordered\"><item>skin blistering or peeling</item></list></td><td colspan=\"2\"><list listType=\"unordered\"><item>swollen lymph nodes</item></list></td></tr><tr><td colspan=\"4\"><paragraph><content styleCode=\"bold\">Problems can also happen in other organs and tissues. These are not all of the signs and symptoms of immune system problems that can happen with penpulimab-kcqx. Call or see your healthcare provider right away for any new or worsening signs or symptoms, which may include:</content></paragraph><list listType=\"unordered\"><item>chest pain, irregular heartbeat, shortness of breath, swelling of ankles</item><item>confusion, sleepiness, memory problems, changes in mood or behavior, stiff neck, balance problems, tingling or numbness of the arms or legs</item><item>double vision, blurry vision, sensitivity to light, eye pain, changes in eyesight</item><item>persistent or severe muscle pain or weakness, muscle cramps</item><item>low red blood cells, bruising</item></list></td></tr><tr><td colspan=\"4\"><paragraph><content styleCode=\"bold\">Infusion reactions that can sometimes be severe or life-threatening</content>. Signs and symptoms of infusion reactions may include: </paragraph></td></tr><tr><td colspan=\"2\"><list listType=\"unordered\"><item>chills or shaking</item></list></td><td colspan=\"2\"><list listType=\"unordered\"><item>dizziness</item></list></td></tr><tr><td colspan=\"2\"><list listType=\"unordered\"><item>itching or rash</item></list></td><td colspan=\"2\"><list listType=\"unordered\"><item>feeling like passing out</item></list></td></tr><tr><td colspan=\"2\"><list listType=\"unordered\"><item>flushing</item></list></td><td colspan=\"2\"><list listType=\"unordered\"><item>fever</item></list></td></tr><tr><td colspan=\"2\"><list listType=\"unordered\"><item>shortness of breath or wheezing</item></list></td><td colspan=\"2\"><list listType=\"unordered\"><item>back pain</item></list></td></tr><tr><td colspan=\"4\"><paragraph><content styleCode=\"bold\">Rejection of a transplanted organ or tissue. </content>Your healthcare provider should tell you what signs and symptoms you should report and monitor you depending on the type of organ or tissue transplant that you have had. </paragraph><paragraph><content styleCode=\"bold\">Complications, including graft-versus-host-disease (GVHD), in people who have received a bone marrow (stem cell) transplant that uses donor stem cells (allogeneic).</content> These complications can be serious and can lead to death. These complications may happen if you underwent transplantation either before or after being treated with penpulimab-kcqx. Your healthcare provider will monitor you for these complications. </paragraph><content styleCode=\"bold\">Getting medical treatment right away may help keep these problems from becoming more serious.</content> Your healthcare provider will check for these problems during treatment with penpulimab-kcqx. Your healthcare provider may treat you with corticosteroid or hormone replacement medicines. Your healthcare provider may also need to delay or completely stop treatment with penpulimab-kcqx if you have severe side effects. </td></tr><tr><td colspan=\"4\" styleCode=\"Toprule Botrule\"><paragraph><content styleCode=\"bold\">What is penpulimab-kcqx?</content></paragraph><paragraph>Penpulimab-kcqx is a prescription medicine used to treat adults with a kind of cancer called non-keratinizing nasopharyngeal carcinoma (NPC).</paragraph><list listType=\"unordered\"><item>Penpulimab-kcqx may be used in combination with either the chemotherapy medicines cisplatin or carboplatin and gemcitabine, as your first treatment when your non-keratinizing NPC has returned (recurrent) or has spread to other parts of your body (metastatic).</item><item>Penpulimab-kcqx may be used alone to treat your non-keratinizing NPC when it:</item></list><list listType=\"unordered\" styleCode=\"Circle\"><item>has spread (metastatic), <content styleCode=\"bold\">and</content></item><item>you received chemotherapy that contains platinum and at least 1 other type of treatment, and it did not work or is no longer working.</item></list> It is not known if penpulimab-kcqx is safe and effective in children. </td></tr><tr><td colspan=\"4\" styleCode=\"Botrule\"><paragraph><content styleCode=\"bold\">Before receiving penpulimab-kcqx, tell your healthcare provider about all of your medical conditions, including if you:</content></paragraph><list listType=\"unordered\"><item>have immune system problems such as Crohn&#x2019;s disease, ulcerative colitis, or lupus</item><item>have received an organ transplant, including corneal transplant</item><item>have received or plan to receive a stem cell transplant that uses donor stem cells (allogeneic)</item><item>have received radiation treatment to your chest area</item><item>have a condition that affects your nervous system, such as myasthenia gravis or Guillain-Barr&#xE9; syndrome</item><item>are pregnant or plan to become pregnant. Penpulimab-kcqx can harm your unborn baby.</item></list><paragraph><content styleCode=\"bold\">Females who are able to become pregnant:</content></paragraph><list listType=\"unordered\" styleCode=\"Circle\"><item>Your healthcare provider will give you a pregnancy test before you start treatment with penpulimab-kcqx.</item></list><list listType=\"unordered\" styleCode=\"Circle\"><item>You should use an effective method of birth control during your treatment and for 4 months after your last dose of penpulimab-kcqx. Talk to your healthcare provider about birth control methods that you can use during this time.</item><item>Tell your healthcare provider right away if you become pregnant or think you may be pregnant during treatment with penpulimab-kcqx.</item></list><list listType=\"unordered\"><item>are breastfeeding or plan to breastfeed. It is not known if penpulimab-kcqx passes into your breast milk. Do not breastfeed during treatment with penpulimab-kcqx and for 4 months after your last dose of penpulimab-kcqx.</item></list><content styleCode=\"bold\">Tell your healthcare provider about all the medicines you take,</content> including prescription and over-the-counter medicines, vitamins, and herbal supplements. </td></tr><tr><td colspan=\"4\" styleCode=\"Botrule\"><paragraph><content styleCode=\"bold\">How will I receive penpulimab-kcqx?</content></paragraph><list listType=\"unordered\"><item>Your healthcare provider will give you penpulimab-kcqx into your vein through an intravenous (IV) line over 60 minutes.</item><item>Penpulimab-kcqx is usually given every 2 or 3 weeks.</item><item>Your healthcare provider will decide how many treatments you need.</item><item>Your healthcare provider will test your blood to check you for certain side effects.</item><item>If you miss any appointments, call your healthcare provider as soon as possible to reschedule your appointment.</item></list></td></tr><tr><td colspan=\"4\"><paragraph><content styleCode=\"bold\">What are the possible side effects of penpulimab-kcqx?</content></paragraph><paragraph><content styleCode=\"bold\">Penpulimab-kcqx can cause serious side effects. See &#x201C;What is the most important information I should know about penpulimab-kcqx?&#x201D;</content></paragraph><paragraph><content styleCode=\"bold\">The most common side effects of penpulimab-kcqx when used in combination with either cisplatin or carboplatin and gemcitabine include:</content></paragraph></td></tr><tr><td colspan=\"2\"><list listType=\"unordered\"><item>nausea</item></list></td><td><list listType=\"unordered\"><item>decreased appetite</item></list></td><td><list listType=\"unordered\"><item>feeling tired</item></list></td></tr><tr><td colspan=\"2\"><list listType=\"unordered\"><item>vomiting</item></list></td><td><list listType=\"unordered\"><item>decreased weight</item></list></td><td><list listType=\"unordered\"><item>rash</item></list></td></tr><tr><td colspan=\"2\"><list listType=\"unordered\"><item>low thyroid hormone levels</item></list></td><td><list listType=\"unordered\"><item>cough</item></list></td><td><list listType=\"unordered\"><item>fever</item></list></td><td colspan=\"4\"/></tr><tr><td colspan=\"2\" rowspan=\"1\"><list listType=\"unordered\"><item>constipation</item></list></td><td rowspan=\"1\"><list listType=\"unordered\"><item>COVID-19 infection</item></list></td><td rowspan=\"1\"/></tr><tr><td colspan=\"4\" styleCode=\"Botrule\"><paragraph><content styleCode=\"bold\">The most common side effects of penpulimab-kcqx when used alone include</content> low red blood cell count (anemia) and low thyroid hormone levels. </paragraph><paragraph>These are not all the possible side effects of penpulimab-kcqx.</paragraph> Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088. </td></tr><tr><td colspan=\"4\" styleCode=\"Botrule\"><paragraph><content styleCode=\"bold\">General information about the safe and effective use of penpulimab-kcqx.</content></paragraph> Medicines are sometimes prescribed for purposes other than those listed in a Medication Guide. You can ask your pharmacist or healthcare provider for information about penpulimab-kcqx that is written for healthcare professionals. </td></tr><tr><td colspan=\"4\"><paragraph><content styleCode=\"bold\">What are the ingredients in penpulimab-kcqx?</content></paragraph><paragraph><content styleCode=\"bold\">Active ingredient:</content> penpulimab-kcqx </paragraph><paragraph><content styleCode=\"bold\">Inactive ingredients: </content>acetic acid, polysorbate 80, sodium acetate, sorbitol, and Water for Injection. </paragraph><paragraph><content styleCode=\"bold\">Manufactured by: </content>Akeso Biopharma Co., Ltd., 6 Shennong Road, Torch Development Zone, Zhongshan, Guangdong 528437, China </paragraph><paragraph>U.S. License No. xxxx</paragraph> For more information, call 833-662-5376 or go to https://www.akesobio.com/en/. </td></tr></tbody></table>"],"mechanism_of_action":["12.1 Mechanism of Action Binding of the PD-1 ligands, PD-L1 and PD-L2, to the PD-1 receptor found on T cells, inhibits T-cell proliferation and cytokine production. Upregulation of PD-1 ligands occurs in some tumors and signaling through this pathway can contribute to inhibition of active T-cell immune surveillance of tumors. Penpulimab-kcqx injection is a humanized IgG1 monoclonal antibody that binds to PD-1 and blocks its interaction with PD-L1 and PD-L2, releasing PD-1 pathway-mediated inhibition of the immune response, including the anti-tumor immune response. In murine tumor models, blocking PD-1 activity resulted in decreased tumor growth."],"clinical_pharmacology":["12 CLINICAL PHARMACOLOGY 12.1 Mechanism of Action Binding of the PD-1 ligands, PD-L1 and PD-L2, to the PD-1 receptor found on T cells, inhibits T-cell proliferation and cytokine production. Upregulation of PD-1 ligands occurs in some tumors and signaling through this pathway can contribute to inhibition of active T-cell immune surveillance of tumors. Penpulimab-kcqx injection is a humanized IgG1 monoclonal antibody that binds to PD-1 and blocks its interaction with PD-L1 and PD-L2, releasing PD-1 pathway-mediated inhibition of the immune response, including the anti-tumor immune response. In murine tumor models, blocking PD-1 activity resulted in decreased tumor growth. 12.2 Pharmacodynamics Penpulimab-kcqx exposure-response relationships and the time course of pharmacodynamic response are not fully characterized. 12.3 Pharmacokinetics Penpulimab-kcqx exposure increased dose proportionally over the dose range of 1 to 10 mg/kg (0.35 to 3.5 times the approved recommended dosage in a 70 kg patient) after the first dose. The mean accumulation ratio was 1.5 for maximum concentration (C max ) and 2.1 for area under the concentration curve (AUC) following multiple doses of 200 mg every 3 weeks. Steady-state concentrations of penpulimab-kcqx were reached by Week 15, with mean (CV%) steady-state trough and peak concentrations of 30 μg/mL (38%) and 88 μg/mL (21%), respectively. Distribution The mean (CV%) volume of distribution was 10 L (44%). Elimination The mean (CV%) clearance was 0.2 L/day (33%) and the mean (CV%) terminal half-life was 32 days (44%). Metabolism Penpulimab-kcqx is expected to be metabolized into small peptides by catabolic pathways. Specific Populations No clinically significant differences in the pharmacokinetics of penpulimab-kcqx were observed based on body weight (32 to 113 kg), age (18 to 91 years), sex, race (White and Asian), serum albumin (22 to 54.5 g/L), baseline LDH (111 to 4,450 IU/L), baseline C-reactive protein (0 to 328 mg/L), baseline ECOG score (0 and 1), immunogenicity status, tumor type (NPC and other tumors), co-administration (with chemotherapy), mild or moderate renal impairment (creatinine clearance [CLcr] ≥ 30 mL/min), mild (total bilirubin ≤ ULN and AST > ULN or total bilirubin > 1 to 1.5 times ULN and any AST) or moderate hepatic impairment (total bilirubin > 1.5 to 3 times ULN and any AST). The effect of severe hepatic (total bilirubin > 3 times ULN and any AST) or renal impairment (CLcr < 30 mL/min) on the pharmacokinetics of penpulimab-kcqx is unknown. 12.6 Immunogenicity The observed incidence of anti-drug antibodies is highly dependent on the sensitivity and specificity of the assay. Differences in assay methods preclude meaningful comparisons of the incidence of anti-drug antibodies in the studies described below with the incidence of anti-drug antibodies in other studies, including those of penpulimab-kcqx or of other penpulimab products. Of the 349 evaluable patients who received penpulimab-kcqx 1, 3, 10 mg/kg every two weeks or 200 mg every two weeks or every three weeks as a single agent, 30% (105/349) of patients tested positive for anti-drug antibodies (ADA) at one or more post-baseline timepoints. Of those who tested positive for ADA, 17% (18/105) had neutralizing antibodies against penpulimab-kcqx. Of the 371 evaluable patients who received penpulimab-kcqx 200 mg every 3 weeks in combination with chemotherapy, 24% (88/371) of patients tested positive for ADA at one or more post-baseline timepoints. Of those who tested positive for ADA, 44% (39/88) had neutralizing antibodies against penpulimab-kcqx. There are insufficient data to assess whether the observed anti-penpulimab-kcqx antibodies affect the safety or effectiveness of penpulimab-kcqx."],"indications_and_usage":["1 INDICATIONS AND USAGE Penpulimab-kcqx is a programmed death receptor-1 (PD-1)-blocking antibody indicated: in combination with either cisplatin or carboplatin and gemcitabine for the first-line treatment of adults with recurrent or metastatic non-keratinizing nasopharyngeal carcinoma (NPC) ( 1.1 ) as a single agent for the treatment of adults with metastatic non-keratinizing NPC with disease progression on or after platinum-based chemotherapy and at least one other prior line of therapy. ( 1.2 ) 1.1 First-line Treatment of Recurrent or Metastatic Non-Keratinizing Nasopharyngeal Carcinoma Penpulimab-kcqx, in combination with either cisplatin or carboplatin and gemcitabine, is indicated for the first-line treatment of adults with recurrent or metastatic non-keratinizing nasopharyngeal carcinoma (NPC). 1.2 Recurrent Metastatic Non-Keratinizing Nasopharyngeal Carcinoma Penpulimab-kcqx, as a single agent, is indicated for the treatment of adults with metastatic non-keratinizing NPC and disease progression on or after platinum-based chemotherapy and at least one other prior line of therapy."],"warnings_and_cautions":["5 WARNINGS AND PRECAUTIONS Immune-Mediated Adverse Reactions ( 5.1 ) o Immune-mediated adverse reactions, which may be severe or fatal, can occur in any organ system or tissue, including the following: immune-mediated pneumonitis, immune-mediated colitis, immune-mediated hepatitis and hepatotoxicity, immune-mediated endocrinopathies, immune-mediated dermatologic adverse reactions, immune-mediated nephritis and renal dysfunction, immune-mediated dermatologic adverse reactions and solid organ transplant rejection. o Monitor for early identification and management. Evaluate liver enzymes, creatinine, and thyroid function at baseline and periodically during treatment. o Withhold or permanently discontinue penpulimab-kcqx based on severity and type of reaction. Infusion-Related Reactions: Interrupt, slow the rate of infusion, or permanently discontinue penpulimab-kcqx based on the severity of the reaction. ( 5.2 ) Complications of Allogeneic HSCT: Fatal and other serious complications can occur in patients who receive allogeneic HSCT before or after being treated with a PD-1/PD-L1 blocking antibody. ( 5.3 ) Embryo-Fetal Toxicity: Can cause fetal harm. Advise females of reproductive potential of the potential risk to a fetus and to use effective contraception. ( 5.4 , 8.1 , 8.3 ) 5.1 Severe and Fatal Immune-Mediated Adverse Reactions Penpulimab-kcqx is a monoclonal antibody that belongs to a class of drugs that bind to either the programmed death-receptor 1 (PD-1) or the PD-ligand 1 (PD-L1), blocking the PD-1/PD-L1 pathway, thereby removing inhibition of the immune response, potentially breaking peripheral tolerance and inducing immune-mediated adverse reactions. Important immune-mediated adverse reactions listed under WARNINGS AND PRECAUTIONS may not include all possible severe and fatal immune-mediated reactions. Immune-mediated adverse reactions, which may be severe or fatal, can occur in any organ system or tissue and can affect more than one body system simultaneously. Immune-mediated adverse reactions can occur at any time after starting treatment with a PD-1/PD- L1 blocking antibody. While immune-mediated adverse reactions usually manifest during treatment with PD-1/PD-L1 blocking antibodies, immune-mediated adverse reactions can also manifest after discontinuation of PD-1/PD-L1 blocking antibodies. Early identification and management of immune-mediated adverse reactions are essential to ensure safe use of PD-1/PD-L1 blocking antibodies. Monitor patients closely for symptoms and signs that may be clinical manifestations of underlying immune-mediated adverse reactions. Evaluate liver enzymes, creatinine, and thyroid function at baseline and periodically during treatment. In cases of suspected immune-mediated adverse reactions, initiate appropriate workup to exclude alternative etiologies, including infection. Institute medical management promptly, including specialty consultation as appropriate. Withhold or permanently discontinue penpulimab-kcqx depending on severity [see Dosage and Administration (2) ] . In general, if penpulimab-kcqx requires interruption or discontinuation, administer systemic corticosteroid therapy (1 mg to 2 mg/kg/day prednisone or equivalent) until improvement to Grade 1 or less. Upon improvement to Grade 1 or less, initiate corticosteroid taper and continue to taper over at least 1 month [ see Dosage and A dministration (2) ] . Consider administration of other systemic immunosuppressants in patients whose immune-mediated adverse reactions are not controlled with corticosteroid therapy. Toxicity management guidelines for adverse reactions that do not necessarily require systemic steroids (e.g., endocrinopathies and dermatologic reactions) are discussed below. Immune-Mediated Pneumonitis Penpulimab-kcqx can cause immune-mediated pneumonitis. In patients treated with other PD-1/PD-L1 blocking antibodies, the incidence of pneumonitis is higher in patients who have received prior thoracic radiation. Penpulimab-kcqx in Combination with Either Cisplatin or Carboplatin and Gemcitabine Immune-mediated pneumonitis occurred in 0.7% (1/146) of patients receiving penpulimab-kcqx, which was a Grade 2 (0.7%) adverse reaction. Systemic corticosteroids were required in the patient. Pneumonitis led to withholding of penpulimab-kcqx in the patient. Penpulimab-kcqx as a Single Agent Immune-mediated pneumonitis occurred in 1.3% (5/372) of patients receiving penpulimab-kcqx, including Grade 3 (0.5%), Grade 2 (0.5%) and Grade 1 (0.3%) adverse reactions. Systemic corticosteroids were required in 80% (4/5) of patients with pneumonitis. Pneumonitis led to permanent discontinuation of penpulimab-kcqx in 0.8% (3/372). Pneumonitis resolved in 20% (1/5) of these patients. Immune -Mediated Colitis Penpulimab-kcqx can cause immune-mediated colitis, which may present with diarrhea. Cytomegalovirus (CMV) infection/reactivation can occur in patients with corticosteroid-refractory immune-mediated colitis. In cases of corticosteroid-refractory colitis, consider repeating infectious workup to exclude alternative etiologies. Penpulimab-kcqx as a Single Agent Immune-mediated colitis occurred in 1.1% (4/372) of patients receiving penpulimab-kcqx, including Grade 2 (0.8%) and Grade 1 (0.3%) adverse reactions. Systemic corticosteroids were required in 75% (3/4) of patients with colitis. Colitis led to withholding of penpulimab-kcqx in 0.8% (3/372) of patients. Immune-Mediated Hepatitis and Hepatotoxicity Penpulimab-kcqx can cause immune-mediated hepatitis. Penpulimab-kcqx in Combination with Either Cisplatin or Carboplatin and Gemcitabine Immune-mediated hepatitis occurred in 0.7% (1/146) of patients receiving penpulimab-kcqx in combination with either cisplatin or carboplatin and gemcitabine, which was a Grade 2 (0.7%) adverse reaction. Systemic corticosteroids and withholding of penpulimab-kcqx were required in this patient. Penpulimab-kcqx as a Single Agent Immune-mediated hepatitis occurred in 3.8% (14/372) of patients receiving penpulimab-kcqx, including Grade 3 (0.8%), Grade 2 (1.3%) and Grade 1 (1.6%) adverse reactions. Systemic corticosteroids were required in 14% (2/14) of patients with hepatitis. Hepatitis led to permanent discontinuation of penpulimab-kcqx in 0.3% (1/372) and withholding of penpulimab-kcqx in 2.2% (8/372) of patients. Hepatitis resolved in 64% (9/14) of these patients. Immune-Mediated Endocrinopathies Adrenal Insufficiency Penpulimab-kcqx can cause primary or secondary adrenal insufficiency. For Grade 2 or higher adrenal insufficiency, initiate symptomatic treatment, including hormone replacement as clinically indicated. Withhold penpulimab-kcqx depending on severity [see Dosage and Administration (2.2) ]. Hypophysitis Penpulimab-kcqx can cause immune-mediated hypophysitis. Hypophysitis can present with acute symptoms associated with mass effect such as headache, photophobia, or visual field defects. Hypophysitis can cause hypopituitarism. Initiate hormone replacement as indicated. Withhold or permanently discontinue penpulimab-kcqx depending on severity [see Dosage and Administration (2.2) ]. Thyroid Disorders: Penpulimab-kcqx can cause immune-mediated thyroid disorders. Thyroiditis can present with or without endocrinopathy. Hypothyroidism can follow hyperthyroidism. Initiate hormone replacement therapy for hypothyroidism or institute medical management of hyperthyroidism as clinically indicated. Withhold or permanently discontinue penpulimab-kcqx based on the severity [ see Dosage and Administration (2) ] . Penpulimab-kcqx in Combination with Either Cisplatin or Carboplatin and Gemcitabine Hyperthyroidism: Immune-mediated hyperthyroidism occurred in 2.1% (3/146) of patients receiving penpulimab-kcqx in combination with either cisplatin or carboplatin and gemcitabine, including Grade 2 (0.7%) and Grade 1 (1.4%) adverse reactions. Hypothyroidism: Immune-mediated hypothyroidism occurred in 16% (26/146) of patients receiving penpulimab-kcqx in combination with either cisplatin or carboplatin and gemcitabine, including Grade 2 (13%) and Grade 1 (4.8%) adverse reactions. Penpulimab-kcqx was withheld in 0.7% (1/146) of patients. Hypothyroidism resolved in 12% (3/26) of these patients. Penpulimab-kcqx as a Single Agent Thyroiditis: Thyroiditis occurred in 0.5% (2/372) of patients receiving penpulimab-kcqx, including Grade 2 (0.3%) and Grade 1 (0.3%) adverse reactions. Thyroiditis led to withholding of penpulimab-kcqx in 0.3% (1/372) of patients. Thyroiditis was resolved in 50% (1/2) of patients. Hyperthyroidism: Immune-mediated hyperthyroidism occurred in 7% (24/372) of patients receiving penpulimab-kcqx, including Grade 2 (1.1%) and Grade 1 (5%) adverse reactions. Penpulimab-kcqx was withheld in 0.5% (2/372) of patients. Hyperthyroidism resolved in 79% (19/24) of these patients. Hypothyroidism: Immune-mediated hypothyroidism occurred in 19% (69/372) of patients receiving penpulimab-kcqx, including Grade 2 (7%) and Grade 1 (12%) adverse reactions. Penpulimab-kcqx was withheld in 1.6% (6/372) of patients. Hypothyroidism resolved in 48% (33/69) of these patients. Type 1 Diabetes Mellitus, which can present with Diabetic Ketoacidosis Monitor patients for hyperglycemia or other signs and symptoms of diabetes. Initiate treatment with insulin as clinically indicated. Withhold penpulimab-kcqx depending on severity [ see Dosage and Administration (2) ]. Penpulimab-kcqx in Combination with Either Cisplatin or Carboplatin and Gemcitabine Diabetes occurred in 2.7% (4/146) of patients receiving penpulimab-kcqx in combination with either cisplatin or carboplatin and gemcitabine, including Grade 4 (0.7%), Grade 3 (0.7%), Grade 2 (0.7%) and Grade 1 (0.7%) adverse reactions. Diabetes led to permanent discontinuation of penpulimab-kcqx in 0.7% (1/146) and withholding of penpulimab-kcqx in 0.7% (1/146) of patients. Diabetes was resolving in 75% (3/4) of these patients. Penpulimab-kcqx as a Single Agent Diabetes occurred in 0.8% (3/372) of patients receiving penpulimab-kcqx as a single agent, including Grade 1 (0.8%) adverse reactions. Diabetes resolved in 67% (2/3) of these patients. Immune-Mediated Nephritis with Renal Dysfunction Penpulimab-kcqx can cause immune-mediated nephritis and renal dysfunction. Penpulimab-kcqx as a Single Agent Immune-mediated nephritis occurred in 0.5% (2/372) of patients receiving penpulimab-kcqx, including Grade 3 (0.3%) and Grade 2 (0.3%) adverse reactions. Immune-mediated nephritis led to permanent discontinuation of penpulimab-kcqx in 0.5% (2/372) of patients. Systemic corticosteroids were required in 50% (1/2) of patients. Nephritis resolved in 50% (1/2) of these patients. Immune-Mediated Dermatolog ic Adverse Reactions Penpulimab-kcqx can cause immune-mediated rash or dermatitis. Exfoliative dermatitis, including Stevens Johnson Syndrome (SJS), Drug Rash with Eosinophilia and Systemic Symptoms (DRESS), and Toxic Epidermal Necrolysis (TEN) has occurred with PD-1/L-1 blocking antibodies. Topical emollients and/or topical corticosteroids may be adequate to treat mild to moderate non-exfoliative rashes. Withhold or permanently discontinue penpulimab-kcqx depending on severity [see Dosage and Administration (2) ] . Penpulimab-kcqx in Combination with Either Cisplatin or Carboplatin and Gemcitabine Immune-mediated rash or dermatitis occurred in 10% (14/146) of patients receiving penpulimab-kcqx in combination with either cisplatin or carboplatin and gemcitabine, including Grade 3 (0.7%), Grade 2 (4.8%) and Grade 1 (4.1%) adverse reactions. Systemic corticosteroids were required in 36% (5/14) of patients with immune-mediated rash or dermatitis. Immune-mediated rash or dermatitis led to withholding of penpulimab-kcqx in 1.4% (2/146) of patients. Immune-mediated rash or dermatitis resolved in 78.6% (11/14) of these patients. Penpulimab-kcqx as a Single Agent Immune-mediated rash or dermatitis occurred in 12% (43/372) of patients receiving penpulimab-kcqx, including Grade 3 (1.3%), Grade 2 (3.5%) and Grade 1 (7%) adverse reactions. Systemic corticosteroids were required in 14% (6/43) of patients with immune-mediated rash or dermatitis. Immune-mediated rash or dermatitis led to permanent discontinuation of penpulimab-kcqx in 0.3% (1/372) and withholding of penpulimab-kcqx in 1.6% (6/372) of patients. Immune-mediated rash or dermatitis resolved in 58% (25/43) of these patients. Other Immune-Mediated Adverse Reactions The following clinically significant immune-mediated adverse reactions occurred at an incidence of <1% (unless otherwise noted) in patients who received penpulimab-kcqx in combination with either cisplatin or carboplatin and gemcitabine or single-agent penpulimab-kcqx or were reported with the use of other PD-1/PD-L1 blocking antibodies. Severe or fatal cases have been reported for some of these adverse reactions. Cardiac/vascular: Myocarditis, pericarditis, vasculitis. Nervous system: Meningitis, encephalitis, myelitis and demyelination, myasthenic syndrome/myasthenia gravis (including exacerbation), Guillain-Barré syndrome, nerve paresis, autoimmune neuropathy, nerve injury. Ocular: Uveitis, iritis, and other ocular inflammatory toxicities can occur. Some cases can be associated with retinal detachment. Various grades of visual impairment including blindness can occur. If uveitis occurs in combination with other immune-mediated adverse reactions, consider a Vogt-Koyanagi-Harada-like syndrome, as this may require treatment with systemic steroids to reduce the risk of permanent vision loss. Gastrointestinal: Pancreatitis to include increases in serum amylase and lipase levels, gastritis, duodenitis. Musculoskeletal and Connective Tissue : Myositis/polymyositis, rhabdomyolysis and associated sequelae including renal failure, arthritis, polymyalgia rheumatic. Endocrine: Hypoparathyroidism. Hematologic/Immune: Hemolytic anemia, aplastic anemia, hemophagocytic lymphohistiocytosis, systemic inflammatory response syndrome, histiocytic necrotizing lymphadenitis (Kikuchi lymphadenitis), sarcoidosis, immune thrombocytopenic purpura, solid organ transplant rejection, other transplant (including corneal graft) rejection. 5.2 Infusion-Related Reactions Penpulimab-kcqx can cause severe or life-threatening infusion-related reactions, including hypersensitivity and anaphylaxis. Discontinue penpulimab-kcqx in patients with severe or life-threatening infusion-related reactions. Interrupt or slow the rate of infusion in patients with mild or moderate infusion-related reactions [see Dosage and Administration (2) ]. Penpulimab-kcqx in Combination with Either Cisplatin or Carboplatin and Gemcitabine Infusion-related reactions occurred in 3.4% of 146 patients receiving penpulimab-kcqx in combination with either cisplatin or carboplatin and gemcitabine, including Grade 2 (1.4%) and Grade 1 (2.1%) infusion related reactions. Penpulimab-kcqx as a Single Agent Infusion-related reactions occurred in 10% of 372 patients receiving penpulimab-kcqx as single agent, including Grade 4 (0.3%), Grade 3 (0.3%), Grade 2 (6%) and Grade 1 (3.8%) infusion related reactions. Penpulimab-kcqx was withheld in 0.8% (3/372) and permanently discontinued in 0.3% (1/372) of patients. 5.3 Complications of Allogeneic HSCT Fatal and other serious complications can occur in patients who receive allogeneic hematopoietic stem cell transplantation (HSCT) before or after being treated with a PD-1/PD-L1 blocking antibody. Transplant-related complications include hyperacute graft-versus-host-disease (GVHD), acute GVHD, chronic GVHD, hepatic veno-occlusive disease (VOD) after reduced intensity conditioning, and steroid-requiring febrile syndrome (without an identified infectious cause) [see Adverse Reactions (6.1) ]. These complications may occur despite intervening therapy between PD-1/PD-L1 blockade and Allogeneic HSCT. Follow patients closely for evidence of transplant-related complications and intervene promptly. Consider the benefit versus risks of treatment with a PD-1/PD-L1 blocking antibody prior to or after an Allogeneic HSCT. 5.4 Embryo-Fetal Toxicity Based on its mechanism of action, penpulimab-kcqx can cause fetal harm when administered to a pregnant woman. Animal studies have demonstrated that inhibition of the PD-1/PD-L1 pathway can lead to increased risk of immune-mediated rejection of the developing fetus resulting in fetal death. Advise pregnant women of the potential risk to a fetus. Advise females of reproductive potential to use effective contraception during treatment with penpulimab-kcqx and for 4 months after the last dose [see Use in Specific Populations ( 8.1 , 8.3 ) ]."],"clinical_studies_table":["<table border=\"0\" width=\"100%\"><tbody><tr><td styleCode=\"Lrule Rrule Toprule Botrule\">Endpoint</td><td styleCode=\"Lrule Rrule Toprule Botrule\"><paragraph>Penpulimab-kcqx</paragraph><paragraph>cisplatin or carboplatin</paragraph><paragraph>and gemcitabine</paragraph> N=144 </td><td styleCode=\"Lrule Rrule Toprule Botrule\"><paragraph>Placebo</paragraph><paragraph>cisplatin or carboplatin</paragraph><paragraph>and gemcitabine</paragraph> N=147 </td></tr><tr><td colspan=\"3\" styleCode=\"Lrule Rrule Toprule Botrule\"><paragraph>BICR-assessed</paragraph> Progression-free Survival </td></tr><tr><td styleCode=\"Lrule Rrule Toprule Botrule\">Number of Events n (%)</td><td styleCode=\"Lrule Rrule Toprule Botrule\">80 (56)</td><td styleCode=\"Lrule Rrule Toprule Botrule\">109 (74)</td></tr><tr><td styleCode=\"Lrule Rrule Toprule Botrule\">Median, months (95% CI)</td><td styleCode=\"Lrule Rrule Toprule Botrule\">9.6 (7.1, 12.5)</td><td styleCode=\"Lrule Rrule Toprule Botrule\">7.0 (6.9, 7.3)</td></tr><tr><td styleCode=\"Lrule Rrule Toprule Botrule\">Hazard Ratio (95% CI) <sup>&#x2020;</sup></td><td colspan=\"2\" rowspan=\"1\" styleCode=\"Lrule Rrule Toprule Botrule\">0.45 (0.33, 0.62)</td></tr><tr><td styleCode=\"Lrule Rrule Toprule Botrule\">p-value <sup>&#x2021;</sup></td><td colspan=\"2\" rowspan=\"1\" styleCode=\"Lrule Rrule Toprule Botrule\">&lt;0.0001</td></tr></tbody></table>","<table border=\"1\" cellpadding=\"0\" cellspacing=\"0\"><tbody><tr><td styleCode=\"Lrule Rrule Toprule Botrule\" valign=\"top\"><paragraph><content styleCode=\"bold\">Efficacy Parameter</content></paragraph></td><td styleCode=\"Lrule Rrule Toprule Botrule\" valign=\"top\"><paragraph><content styleCode=\"bold\">Penpulimab-kcqx</content></paragraph><paragraph><content styleCode=\"bold\">(</content><content styleCode=\"bold\">N=125)</content></paragraph></td></tr><tr><td styleCode=\"Lrule Rrule Toprule Botrule\" valign=\"top\"><paragraph><content styleCode=\"bold\">Objective Response Rate,</content>% (95% CI) </paragraph></td><td styleCode=\"Lrule Rrule Toprule Botrule\" valign=\"top\"><paragraph>28 (20, 37)</paragraph></td></tr><tr><td styleCode=\"Lrule Rrule Toprule Botrule\" valign=\"top\"><paragraph>Complete response rate, %</paragraph></td><td styleCode=\"Lrule Rrule Toprule Botrule\" valign=\"top\"><paragraph>0.8</paragraph></td></tr><tr><td styleCode=\"Lrule Rrule Toprule Botrule\" valign=\"top\"><paragraph>Partial response rate, %</paragraph></td><td styleCode=\"Lrule Rrule Toprule Botrule\" valign=\"top\"><paragraph>27</paragraph></td></tr><tr><td styleCode=\"Lrule Rrule Toprule Botrule\" valign=\"top\"><paragraph><content styleCode=\"bold\">Duration of Response (DOR)</content></paragraph></td><td styleCode=\"Lrule Rrule Toprule Botrule\" valign=\"top\"><paragraph>N=35</paragraph></td></tr><tr><td styleCode=\"Lrule Rrule Toprule Botrule\" valign=\"top\"><paragraph>Median <sup>a</sup>, months (95% CI) </paragraph></td><td styleCode=\"Lrule Rrule Toprule Botrule\" valign=\"top\"><paragraph>NR (9.2, NE)</paragraph></td></tr><tr><td styleCode=\"Lrule Rrule Toprule Botrule\" valign=\"top\"><paragraph>Patients with DOR &#x2265; 12 months (%) <sup>b</sup></paragraph></td><td styleCode=\"Lrule Rrule Toprule Botrule\" valign=\"top\"><paragraph>46</paragraph></td></tr></tbody></table>"],"nonclinical_toxicology":["13 NONCLINICAL TOXICOLOGY 13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility No studies have been performed to assess the potential of penpulimab-kcqx for carcinogenicity or genotoxicity. Fertility studies have not been conducted with penpulimab-kcqx. In 6-week and 3-month repeat dose toxicology studies in monkeys, there were no notable effects in the male and female reproductive organs; however, most animals in these studies were not sexually mature. 13.2 Animal Toxicology and/or Pharmacology In animal models, inhibition of PD-1/PD-L1 signaling increased the severity of some infections and enhanced inflammatory responses. Mycobacterium tuberculosis-infected PD-1 knockout mice exhibit markedly decreased survival compared with wild-type controls, which correlated with increased bacterial proliferation and inflammatory responses in these animals. PD-1 blockade using a primate anti-PD-1 antibody was also shown to exacerbate M. tuberculosis infection in rhesus macaques. PD-1 and PD-L1 knockout mice and mice receiving PD-L1 blocking antibody have also shown decreased survival following infection with lymphocytic choriomeningitis virus."],"adverse_reactions_table":["<table cellpadding=\"0\" cellspacing=\"0\" width=\"100%\"><tbody><tr><td rowspan=\"2\" styleCode=\"Lrule Rrule Toprule Botrule\"><paragraph><content styleCode=\"bold\">Adverse Reaction</content></paragraph></td><td colspan=\"2\" styleCode=\"Lrule Rrule Toprule Botrule\"><paragraph><content styleCode=\"bold\">Penpulimab-kcqx   Cisplatin or Carboplatin and Gemcitabine   N = 146 </content></paragraph></td><td colspan=\"2\" styleCode=\"Lrule Rrule Toprule Botrule\"><paragraph><content styleCode=\"bold\">Placebo   Cisplatin or Carboplatin and Gemcitabine   N = 142 </content></paragraph></td></tr><tr><td styleCode=\"Lrule Rrule Toprule Botrule\"><paragraph><content styleCode=\"bold\">All Grades <sup>1</sup>  (%) </content></paragraph></td><td styleCode=\"Lrule Rrule Toprule Botrule\"><paragraph><content styleCode=\"bold\">Grade 3 or 4 <sup>1</sup>  (%) </content></paragraph></td><td styleCode=\"Lrule Rrule Toprule Botrule\"><paragraph><content styleCode=\"bold\">All Grades <sup>1</sup>  (%) </content></paragraph></td><td styleCode=\"Lrule Rrule Toprule Botrule\"><paragraph><content styleCode=\"bold\">Grade 3 or 4 <sup>1</sup>  (%) </content></paragraph></td></tr><tr><td colspan=\"5\" styleCode=\"Lrule Rrule Toprule Botrule\"><paragraph><content styleCode=\"bold\">Gastrointestinal disorders</content></paragraph></td></tr><tr><td styleCode=\"Lrule Rrule Toprule Botrule\"><paragraph>Nausea</paragraph></td><td styleCode=\"Lrule Rrule Toprule Botrule\"><paragraph>58</paragraph></td><td styleCode=\"Lrule Rrule Toprule Botrule\"><paragraph>2.1</paragraph></td><td styleCode=\"Lrule Rrule Toprule Botrule\"><paragraph>64</paragraph></td><td styleCode=\"Lrule Rrule Toprule Botrule\"><paragraph>0</paragraph></td></tr><tr><td styleCode=\"Lrule Rrule Toprule Botrule\"><paragraph>Vomiting <sup>2</sup></paragraph></td><td styleCode=\"Lrule Rrule Toprule Botrule\"><paragraph>55</paragraph></td><td styleCode=\"Lrule Rrule Toprule Botrule\"><paragraph>1.4</paragraph></td><td styleCode=\"Lrule Rrule Toprule Botrule\"><paragraph>54</paragraph></td><td styleCode=\"Lrule Rrule Toprule Botrule\"><paragraph>1.4</paragraph></td></tr><tr><td styleCode=\"Lrule Rrule Toprule Botrule\"><paragraph>Constipation</paragraph></td><td styleCode=\"Lrule Rrule Toprule Botrule\"><paragraph>41</paragraph></td><td styleCode=\"Lrule Rrule Toprule Botrule\"><paragraph>0</paragraph></td><td styleCode=\"Lrule Rrule Toprule Botrule\"><paragraph>44</paragraph></td><td styleCode=\"Lrule Rrule Toprule Botrule\"><paragraph>0</paragraph></td></tr><tr><td styleCode=\"Lrule Rrule Toprule Botrule\"><paragraph>Abdominal distension</paragraph></td><td styleCode=\"Lrule Rrule Toprule Botrule\"><paragraph>12</paragraph></td><td styleCode=\"Lrule Rrule Toprule Botrule\"><paragraph>0</paragraph></td><td styleCode=\"Lrule Rrule Toprule Botrule\"><paragraph>6</paragraph></td><td styleCode=\"Lrule Rrule Toprule Botrule\"><paragraph>0</paragraph></td></tr><tr><td colspan=\"5\" styleCode=\"Lrule Rrule Toprule Botrule\"><paragraph><content styleCode=\"bold\">Endocrine disorders</content></paragraph></td></tr><tr><td styleCode=\"Lrule Rrule Toprule Botrule\"><paragraph>Hypothyroidism <sup>3</sup></paragraph></td><td styleCode=\"Lrule Rrule Toprule Botrule\"><paragraph>45</paragraph></td><td styleCode=\"Lrule Rrule Toprule Botrule\"><paragraph>0</paragraph></td><td styleCode=\"Lrule Rrule Toprule Botrule\"><paragraph>27</paragraph></td><td styleCode=\"Lrule Rrule Toprule Botrule\"><paragraph>0</paragraph></td></tr><tr><td colspan=\"5\" styleCode=\"Lrule Rrule Toprule Botrule\"><paragraph><content styleCode=\"bold\">Metabolism and nutrition disorders</content></paragraph></td></tr><tr><td styleCode=\"Lrule Rrule Toprule Botrule\"><paragraph>Decreased appetite</paragraph></td><td styleCode=\"Lrule Rrule Toprule Botrule\"><paragraph>36</paragraph></td><td styleCode=\"Lrule Rrule Toprule Botrule\"><paragraph>0</paragraph></td><td styleCode=\"Lrule Rrule Toprule Botrule\"><paragraph>39</paragraph></td><td styleCode=\"Lrule Rrule Toprule Botrule\"><paragraph>0</paragraph></td></tr><tr><td colspan=\"5\" styleCode=\"Lrule Rrule Toprule Botrule\"><paragraph><content styleCode=\"bold\">Investigations</content></paragraph></td></tr><tr><td styleCode=\"Lrule Rrule Toprule Botrule\"><paragraph>Weight decreased</paragraph></td><td styleCode=\"Lrule Rrule Toprule Botrule\"><paragraph>26</paragraph></td><td styleCode=\"Lrule Rrule Toprule Botrule\"><paragraph>1.4</paragraph></td><td styleCode=\"Lrule Rrule Toprule Botrule\"><paragraph>16</paragraph></td><td styleCode=\"Lrule Rrule Toprule Botrule\"><paragraph>0</paragraph></td></tr><tr><td colspan=\"5\" styleCode=\"Lrule Rrule Toprule Botrule\"><paragraph><content styleCode=\"bold\">Respiratory, thoracic and mediastinal disorders</content></paragraph></td></tr><tr><td styleCode=\"Lrule Rrule Toprule Botrule\"><paragraph>Cough <sup>4</sup></paragraph></td><td styleCode=\"Lrule Rrule Toprule Botrule\"><paragraph>25</paragraph></td><td styleCode=\"Lrule Rrule Toprule Botrule\"><paragraph>0</paragraph></td><td styleCode=\"Lrule Rrule Toprule Botrule\"><paragraph>16</paragraph></td><td styleCode=\"Lrule Rrule Toprule Botrule\"><paragraph>0</paragraph></td></tr><tr><td colspan=\"5\" styleCode=\"Lrule Rrule Toprule Botrule\"><paragraph><content styleCode=\"bold\">Infections and infestations</content></paragraph></td></tr><tr><td styleCode=\"Lrule Rrule Toprule Botrule\"><paragraph>COVID-19</paragraph></td><td styleCode=\"Lrule Rrule Toprule Botrule\"><paragraph>25</paragraph></td><td styleCode=\"Lrule Rrule Toprule Botrule\"><paragraph>0</paragraph></td><td styleCode=\"Lrule Rrule Toprule Botrule\"><paragraph>17</paragraph></td><td styleCode=\"Lrule Rrule Toprule Botrule\"><paragraph>0.7</paragraph></td></tr><tr><td colspan=\"5\" styleCode=\"Lrule Rrule Toprule Botrule\"><paragraph><content styleCode=\"bold\">General disorders and administration site conditions</content></paragraph></td></tr><tr><td styleCode=\"Lrule Rrule Toprule Botrule\"><paragraph>Fatigue <sup>5</sup></paragraph></td><td styleCode=\"Lrule Rrule Toprule Botrule\"><paragraph>25</paragraph></td><td styleCode=\"Lrule Rrule Toprule Botrule\"><paragraph>1.4</paragraph></td><td styleCode=\"Lrule Rrule Toprule Botrule\"><paragraph>22</paragraph></td><td styleCode=\"Lrule Rrule Toprule Botrule\"><paragraph>0</paragraph></td></tr><tr><td styleCode=\"Lrule Rrule Toprule Botrule\"><paragraph>Pyrexia</paragraph></td><td styleCode=\"Lrule Rrule Toprule Botrule\"><paragraph>21</paragraph></td><td styleCode=\"Lrule Rrule Toprule Botrule\"><paragraph>0</paragraph></td><td styleCode=\"Lrule Rrule Toprule Botrule\"><paragraph>20</paragraph></td><td styleCode=\"Lrule Rrule Toprule Botrule\"><paragraph>0.7</paragraph></td></tr><tr><td styleCode=\"Lrule Rrule Toprule Botrule\"><paragraph>Malaise</paragraph></td><td styleCode=\"Lrule Rrule Toprule Botrule\"><paragraph>10</paragraph></td><td styleCode=\"Lrule Rrule Toprule Botrule\"><paragraph>0</paragraph></td><td styleCode=\"Lrule Rrule Toprule Botrule\"><paragraph>8</paragraph></td><td styleCode=\"Lrule Rrule Toprule Botrule\"><paragraph>0</paragraph></td></tr><tr><td colspan=\"5\" styleCode=\"Lrule Rrule Toprule Botrule\"><paragraph><content styleCode=\"bold\">Skin and subcutaneous tissue disorders</content></paragraph></td></tr><tr><td styleCode=\"Lrule Rrule Toprule Botrule\"><paragraph>Rash <sup>6</sup></paragraph></td><td styleCode=\"Lrule Rrule Toprule Botrule\"><paragraph>24</paragraph></td><td styleCode=\"Lrule Rrule Toprule Botrule\"><paragraph>1.4</paragraph></td><td styleCode=\"Lrule Rrule Toprule Botrule\"><paragraph>20</paragraph></td><td styleCode=\"Lrule Rrule Toprule Botrule\"><paragraph>0</paragraph></td></tr><tr><td styleCode=\"Lrule Rrule Toprule Botrule\"><paragraph>Pruritus</paragraph></td><td styleCode=\"Lrule Rrule Toprule Botrule\"><paragraph>11</paragraph></td><td styleCode=\"Lrule Rrule Toprule Botrule\"><paragraph>0</paragraph></td><td styleCode=\"Lrule Rrule Toprule Botrule\"><paragraph>11</paragraph></td><td styleCode=\"Lrule Rrule Toprule Botrule\"><paragraph>0</paragraph></td></tr><tr><td colspan=\"5\" styleCode=\"Lrule Rrule Toprule Botrule\"><paragraph><content styleCode=\"bold\">Nervous system disorders</content></paragraph></td></tr><tr><td styleCode=\"Lrule Rrule Toprule Botrule\"><paragraph>Headache</paragraph></td><td styleCode=\"Lrule Rrule Toprule Botrule\"><paragraph>15</paragraph></td><td styleCode=\"Lrule Rrule Toprule Botrule\"><paragraph>0.7</paragraph></td><td styleCode=\"Lrule Rrule Toprule Botrule\"><paragraph>10</paragraph></td><td styleCode=\"Lrule Rrule Toprule Botrule\"><paragraph>0.7</paragraph></td></tr><tr><td styleCode=\"Lrule Rrule Toprule Botrule\"><paragraph>Dizziness <sup>7</sup></paragraph></td><td styleCode=\"Lrule Rrule Toprule Botrule\"><paragraph>14</paragraph></td><td styleCode=\"Lrule Rrule Toprule Botrule\"><paragraph>0</paragraph></td><td styleCode=\"Lrule Rrule Toprule Botrule\"><paragraph>15</paragraph></td><td styleCode=\"Lrule Rrule Toprule Botrule\"><paragraph>0.7</paragraph></td></tr><tr><td colspan=\"5\" styleCode=\"Lrule Rrule Toprule Botrule\"><paragraph><content styleCode=\"bold\">Renal and urinary disorders</content></paragraph></td></tr><tr><td styleCode=\"Lrule Rrule Toprule Botrule\"><paragraph>Proteinuria</paragraph></td><td styleCode=\"Lrule Rrule Toprule Botrule\"><paragraph>14</paragraph></td><td styleCode=\"Lrule Rrule Toprule Botrule\"><paragraph>0</paragraph></td><td styleCode=\"Lrule Rrule Toprule Botrule\"><paragraph>13</paragraph></td><td styleCode=\"Lrule Rrule Toprule Botrule\"><paragraph>0</paragraph></td></tr><tr><td styleCode=\"Lrule Rrule Toprule Botrule\"><paragraph>Acute kidney injury <sup>8</sup></paragraph></td><td styleCode=\"Lrule Rrule Toprule Botrule\"><paragraph>13</paragraph></td><td styleCode=\"Lrule Rrule Toprule Botrule\"><paragraph>1.4</paragraph></td><td styleCode=\"Lrule Rrule Toprule Botrule\"><paragraph>4.9</paragraph></td><td styleCode=\"Lrule Rrule Toprule Botrule\"><paragraph>0</paragraph></td></tr><tr><td colspan=\"5\" styleCode=\"Lrule Rrule Toprule Botrule\"><paragraph><content styleCode=\"bold\">Musculoskeletal and connective tissue disorders</content></paragraph></td></tr><tr><td styleCode=\"Lrule Rrule Toprule Botrule\"><paragraph>Musculoskeletal pain <sup>9</sup></paragraph></td><td styleCode=\"Lrule Rrule Toprule Botrule\"><paragraph>14</paragraph></td><td styleCode=\"Lrule Rrule Toprule Botrule\"><paragraph>0.7</paragraph></td><td styleCode=\"Lrule Rrule Toprule Botrule\"><paragraph>24</paragraph></td><td styleCode=\"Lrule Rrule Toprule Botrule\"><paragraph>0</paragraph></td></tr><tr><td colspan=\"5\" styleCode=\"Lrule Rrule Toprule Botrule\"><paragraph><content styleCode=\"bold\">Psychiatric disorders</content></paragraph></td></tr><tr><td styleCode=\"Lrule Rrule Toprule Botrule\"><paragraph>Insomnia</paragraph></td><td styleCode=\"Lrule Rrule Toprule Botrule\"><paragraph>12</paragraph></td><td styleCode=\"Lrule Rrule Toprule Botrule\"><paragraph>0</paragraph></td><td styleCode=\"Lrule Rrule Toprule Botrule\"><paragraph>10</paragraph></td><td styleCode=\"Lrule Rrule Toprule Botrule\"><paragraph>0</paragraph></td></tr></tbody></table>","<table border=\"1\" cellpadding=\"0\" cellspacing=\"0\" width=\"99%\"><tbody><tr><td styleCode=\"Lrule Rrule Toprule Botrule\"><content styleCode=\"bold\">Laboratory Abnormality</content></td><td colspan=\"2\" rowspan=\"1\" styleCode=\"Lrule Rrule Toprule Botrule\">Penpulimab-kcqx   Cisplatin or Carboplatin /Gemcitabine <sup>2</sup></td><td colspan=\"2\" rowspan=\"1\" styleCode=\"Lrule Rrule Toprule Botrule\">Placebo   Cisplatin or Carboplatin /Gemcitabine <sup>3</sup></td></tr><tr><td styleCode=\"Lrule Rrule Toprule Botrule\"/><td styleCode=\"Lrule Rrule Toprule Botrule\">All Grades <sup>1</sup>  (%) </td><td styleCode=\"Lrule Rrule Toprule Botrule\">Grade 3 or 4 <sup>1</sup>  (%) </td><td styleCode=\"Lrule Rrule Toprule Botrule\">All Grades <sup>1</sup>  (%) </td><td styleCode=\"Lrule Rrule Toprule Botrule\">Grade 3 or 4 <sup>1</sup>  (%) </td></tr><tr><td styleCode=\"Lrule Rrule Toprule Botrule\"><content styleCode=\"bold\">Hematology</content></td><td styleCode=\"Lrule Rrule Toprule Botrule\"/><td styleCode=\"Lrule Rrule Toprule Botrule\"/><td styleCode=\"Lrule Rrule Toprule Botrule\"/><td styleCode=\"Lrule Rrule Toprule Botrule\"/></tr><tr><td styleCode=\"Lrule Rrule Toprule Botrule\">White blood cell decreased</td><td styleCode=\"Lrule Rrule Toprule Botrule\">99</td><td styleCode=\"Lrule Rrule Toprule Botrule\">58</td><td styleCode=\"Lrule Rrule Toprule Botrule\">97</td><td styleCode=\"Lrule Rrule Toprule Botrule\">58</td></tr><tr><td styleCode=\"Lrule Rrule Toprule Botrule\">Hemoglobin decreased</td><td styleCode=\"Lrule Rrule Toprule Botrule\">98</td><td styleCode=\"Lrule Rrule Toprule Botrule\">49</td><td styleCode=\"Lrule Rrule Toprule Botrule\">97</td><td styleCode=\"Lrule Rrule Toprule Botrule\">47</td></tr><tr><td styleCode=\"Lrule Rrule Toprule Botrule\"><paragraph>Lymphocytes decreased</paragraph></td><td styleCode=\"Lrule Rrule Toprule Botrule\">93</td><td styleCode=\"Lrule Rrule Toprule Botrule\">70</td><td styleCode=\"Lrule Rrule Toprule Botrule\">89</td><td styleCode=\"Lrule Rrule Toprule Botrule\">58</td></tr><tr><td styleCode=\"Lrule Rrule Toprule Botrule\">Neutrophils decreased</td><td styleCode=\"Lrule Rrule Toprule Botrule\">92</td><td styleCode=\"Lrule Rrule Toprule Botrule\">61</td><td styleCode=\"Lrule Rrule Toprule Botrule\">95</td><td styleCode=\"Lrule Rrule Toprule Botrule\">65</td></tr><tr><td styleCode=\"Lrule Rrule Toprule Botrule\"><content styleCode=\"bold\">Chemistry</content></td><td styleCode=\"Lrule Rrule Toprule Botrule\"/><td styleCode=\"Lrule Rrule Toprule Botrule\"/><td styleCode=\"Lrule Rrule Toprule Botrule\"/><td styleCode=\"Lrule Rrule Toprule Botrule\"/></tr><tr><td styleCode=\"Lrule Rrule Toprule Botrule\">Magnesium decreased</td><td styleCode=\"Lrule Rrule Toprule Botrule\">69</td><td styleCode=\"Lrule Rrule Toprule Botrule\">4.2</td><td styleCode=\"Lrule Rrule Toprule Botrule\">58</td><td styleCode=\"Lrule Rrule Toprule Botrule\">3.6</td></tr><tr><td styleCode=\"Lrule Rrule Toprule Botrule\">Sodium decreased</td><td styleCode=\"Lrule Rrule Toprule Botrule\">62</td><td styleCode=\"Lrule Rrule Toprule Botrule\">7</td><td styleCode=\"Lrule Rrule Toprule Botrule\">58</td><td styleCode=\"Lrule Rrule Toprule Botrule\">7</td></tr><tr><td styleCode=\"Lrule Rrule Toprule Botrule\">Triglycerides increased</td><td styleCode=\"Lrule Rrule Toprule Botrule\">58</td><td styleCode=\"Lrule Rrule Toprule Botrule\">4.3</td><td styleCode=\"Lrule Rrule Toprule Botrule\">53</td><td styleCode=\"Lrule Rrule Toprule Botrule\">4.3</td></tr><tr><td styleCode=\"Lrule Rrule Toprule Botrule\">Aspartate aminotransferase increased</td><td styleCode=\"Lrule Rrule Toprule Botrule\">52</td><td styleCode=\"Lrule Rrule Toprule Botrule\">6</td><td styleCode=\"Lrule Rrule Toprule Botrule\">37</td><td styleCode=\"Lrule Rrule Toprule Botrule\">2.9</td></tr><tr><td styleCode=\"Lrule Rrule Toprule Botrule\">Cholesterol increased</td><td styleCode=\"Lrule Rrule Toprule Botrule\">49</td><td styleCode=\"Lrule Rrule Toprule Botrule\">2.2</td><td styleCode=\"Lrule Rrule Toprule Botrule\">46</td><td styleCode=\"Lrule Rrule Toprule Botrule\">0.7</td></tr><tr><td styleCode=\"Lrule Rrule Toprule Botrule\">Creatinine increased</td><td styleCode=\"Lrule Rrule Toprule Botrule\">48</td><td styleCode=\"Lrule Rrule Toprule Botrule\">1.4</td><td styleCode=\"Lrule Rrule Toprule Botrule\">39</td><td styleCode=\"Lrule Rrule Toprule Botrule\">0.7</td></tr><tr><td styleCode=\"Lrule Rrule Toprule Botrule\">Albumin decreased</td><td styleCode=\"Lrule Rrule Toprule Botrule\">47</td><td styleCode=\"Lrule Rrule Toprule Botrule\">0</td><td styleCode=\"Lrule Rrule Toprule Botrule\">44</td><td styleCode=\"Lrule Rrule Toprule Botrule\">1.4</td></tr><tr><td styleCode=\"Lrule Rrule Toprule Botrule\">Potassium decreased</td><td styleCode=\"Lrule Rrule Toprule Botrule\">45</td><td styleCode=\"Lrule Rrule Toprule Botrule\">14</td><td styleCode=\"Lrule Rrule Toprule Botrule\">31</td><td styleCode=\"Lrule Rrule Toprule Botrule\">3.6</td></tr><tr><td styleCode=\"Lrule Rrule Toprule Botrule\">Alanine aminotransferase increased</td><td styleCode=\"Lrule Rrule Toprule Botrule\">42</td><td styleCode=\"Lrule Rrule Toprule Botrule\">8</td><td styleCode=\"Lrule Rrule Toprule Botrule\">37</td><td styleCode=\"Lrule Rrule Toprule Botrule\">2.1</td></tr><tr><td styleCode=\"Lrule Rrule Toprule Botrule\">GGT increased</td><td styleCode=\"Lrule Rrule Toprule Botrule\">36</td><td styleCode=\"Lrule Rrule Toprule Botrule\">1.4</td><td styleCode=\"Lrule Rrule Toprule Botrule\">33</td><td styleCode=\"Lrule Rrule Toprule Botrule\">0.7</td></tr><tr><td styleCode=\"Lrule Rrule Toprule Botrule\">Alkaline phosphatase increased</td><td styleCode=\"Lrule Rrule Toprule Botrule\">32</td><td styleCode=\"Lrule Rrule Toprule Botrule\">0.7</td><td styleCode=\"Lrule Rrule Toprule Botrule\">30</td><td styleCode=\"Lrule Rrule Toprule Botrule\">0</td></tr><tr><td styleCode=\"Lrule Rrule Toprule Botrule\">Lipase increased</td><td styleCode=\"Lrule Rrule Toprule Botrule\">28</td><td styleCode=\"Lrule Rrule Toprule Botrule\">11</td><td styleCode=\"Lrule Rrule Toprule Botrule\">23</td><td styleCode=\"Lrule Rrule Toprule Botrule\">3.9</td></tr><tr><td styleCode=\"Lrule Rrule Toprule Botrule\">Chloride decreased</td><td styleCode=\"Lrule Rrule Toprule Botrule\">25</td><td styleCode=\"Lrule Rrule Toprule Botrule\">1.4</td><td styleCode=\"Lrule Rrule Toprule Botrule\">11</td><td styleCode=\"Lrule Rrule Toprule Botrule\">0</td></tr><tr><td styleCode=\"Lrule Rrule Toprule Botrule\">Serum amylase increased</td><td styleCode=\"Lrule Rrule Toprule Botrule\">23</td><td styleCode=\"Lrule Rrule Toprule Botrule\">2.9</td><td styleCode=\"Lrule Rrule Toprule Botrule\">17</td><td styleCode=\"Lrule Rrule Toprule Botrule\">0.7</td></tr><tr><td styleCode=\"Lrule Rrule Toprule Botrule\">Glucose decreased</td><td styleCode=\"Lrule Rrule Toprule Botrule\">22</td><td styleCode=\"Lrule Rrule Toprule Botrule\">1.4</td><td styleCode=\"Lrule Rrule Toprule Botrule\">20</td><td styleCode=\"Lrule Rrule Toprule Botrule\">0.7</td></tr><tr><td styleCode=\"Lrule Rrule Toprule Botrule\">Lipids increased</td><td styleCode=\"Lrule Rrule Toprule Botrule\">21</td><td styleCode=\"Lrule Rrule Toprule Botrule\">1.4</td><td styleCode=\"Lrule Rrule Toprule Botrule\">20</td><td styleCode=\"Lrule Rrule Toprule Botrule\">0.7</td></tr></tbody></table>","<table cellpadding=\"0\" cellspacing=\"0\" width=\"100%\"><tbody><tr><td rowspan=\"2\" styleCode=\"Lrule Rrule Toprule Botrule\"><paragraph><content styleCode=\"bold\">Adverse Reaction</content></paragraph></td><td colspan=\"2\" styleCode=\"Lrule Rrule Toprule Botrule\"><paragraph><content styleCode=\"bold\">Penpulimab-kcqx   N = 130 </content></paragraph></td></tr><tr><td styleCode=\"Lrule Rrule Toprule Botrule\"><paragraph><content styleCode=\"bold\">All   Grades <sup>1</sup></content></paragraph><paragraph><content styleCode=\"bold\">(%)</content></paragraph></td><td styleCode=\"Lrule Rrule Toprule Botrule\"><paragraph><content styleCode=\"bold\">Grade 3 or 4 <sup>1</sup></content></paragraph><paragraph><content styleCode=\"bold\">(%)</content></paragraph></td></tr><tr><td colspan=\"3\" styleCode=\"Lrule Rrule Toprule Botrule\"><paragraph><content styleCode=\"bold\">Endocrine disorders</content></paragraph></td></tr><tr><td styleCode=\"Lrule Rrule Toprule Botrule\"><paragraph>Hypothyroidism <sup>2</sup></paragraph></td><td styleCode=\"Lrule Rrule Toprule Botrule\"><paragraph>39</paragraph></td><td styleCode=\"Lrule Rrule Toprule Botrule\"><paragraph>0</paragraph></td></tr><tr><td colspan=\"3\" styleCode=\"Lrule Rrule Toprule Botrule\"><paragraph><content styleCode=\"bold\">Musculoskeletal and connective tissue disorders</content></paragraph></td></tr><tr><td styleCode=\"Lrule Rrule Toprule Botrule\"><paragraph>Musculoskeletal pain <sup>3</sup></paragraph></td><td styleCode=\"Lrule Rrule Toprule Botrule\"><paragraph>25</paragraph></td><td styleCode=\"Lrule Rrule Toprule Botrule\"><paragraph>0.8</paragraph></td></tr><tr><td colspan=\"3\" styleCode=\"Lrule Rrule Toprule Botrule\"><paragraph><content styleCode=\"bold\">Investigations</content></paragraph></td></tr><tr><td styleCode=\"Lrule Rrule Toprule Botrule\"><paragraph>Weight decreased</paragraph></td><td styleCode=\"Lrule Rrule Toprule Botrule\"><paragraph>19</paragraph></td><td styleCode=\"Lrule Rrule Toprule Botrule\"><paragraph>1.5</paragraph></td></tr><tr><td colspan=\"3\" styleCode=\"Lrule Rrule Toprule Botrule\"><paragraph><content styleCode=\"bold\">General disorders and administration site conditions</content></paragraph></td></tr><tr><td styleCode=\"Lrule Rrule Toprule Botrule\"><paragraph>Pyrexia</paragraph></td><td styleCode=\"Lrule Rrule Toprule Botrule\"><paragraph>15</paragraph></td><td styleCode=\"Lrule Rrule Toprule Botrule\"><paragraph>0</paragraph></td></tr><tr><td colspan=\"3\" styleCode=\"Lrule Rrule Toprule Botrule\"><paragraph><content styleCode=\"bold\">Infections and infestations</content></paragraph></td></tr><tr><td styleCode=\"Lrule Rrule Toprule Botrule\"><paragraph>Upper respiratory tract infection</paragraph></td><td styleCode=\"Lrule Rrule Toprule Botrule\"><paragraph>13</paragraph></td><td styleCode=\"Lrule Rrule Toprule Botrule\"><paragraph>0.8</paragraph></td></tr><tr><td colspan=\"3\" styleCode=\"Lrule Rrule Toprule Botrule\"><paragraph><content styleCode=\"bold\">Respiratory, thoracic and mediastinal disorders</content></paragraph></td></tr><tr><td styleCode=\"Lrule Rrule Toprule Botrule\"><paragraph>Cough <sup>4</sup></paragraph></td><td styleCode=\"Lrule Rrule Toprule Botrule\"><paragraph>11</paragraph></td><td styleCode=\"Lrule Rrule Toprule Botrule\"><paragraph>0</paragraph></td></tr><tr><td colspan=\"3\" styleCode=\"Lrule Rrule Toprule Botrule\"><paragraph><content styleCode=\"bold\">Skin and subcutaneous tissue disorders</content></paragraph></td></tr><tr><td styleCode=\"Lrule Rrule Toprule Botrule\"><paragraph>Rash <sup>5</sup></paragraph></td><td styleCode=\"Lrule Rrule Toprule Botrule\"><paragraph>11</paragraph></td><td styleCode=\"Lrule Rrule Toprule Botrule\"><paragraph>2.3</paragraph></td></tr></tbody></table>","<table cellpadding=\"0\" cellspacing=\"0\" width=\"100%\"><tbody><tr><td rowspan=\"2\" styleCode=\"Lrule Rrule Toprule Botrule\"><paragraph><content styleCode=\"bold\">Laboratory Abnormality</content></paragraph></td><td colspan=\"2\" styleCode=\"Lrule Rrule Toprule Botrule\"><paragraph><content styleCode=\"bold\">Penpulimab-kcqx</content></paragraph></td></tr><tr><td styleCode=\"Lrule Rrule Toprule Botrule\"><paragraph><content styleCode=\"bold\">All Grades <sup>1</sup></content></paragraph><paragraph><content styleCode=\"bold\">(%) <sup>2</sup></content></paragraph></td><td styleCode=\"Lrule Rrule Toprule Botrule\"><paragraph><content styleCode=\"bold\">Grades 3 or 4</content></paragraph><paragraph><content styleCode=\"bold\">(%)</content></paragraph></td></tr><tr><td colspan=\"3\" styleCode=\"Lrule Rrule Toprule Botrule\"><paragraph><content styleCode=\"bold\">Chemistry</content></paragraph></td></tr><tr><td styleCode=\"Lrule Rrule Toprule Botrule\"><paragraph>Creatinine increased</paragraph></td><td styleCode=\"Lrule Rrule Toprule Botrule\"><paragraph>81</paragraph></td><td styleCode=\"Lrule Rrule Toprule Botrule\"><paragraph>0</paragraph></td></tr><tr><td styleCode=\"Lrule Rrule Toprule Botrule\"><paragraph>Phosphate decreased</paragraph></td><td styleCode=\"Lrule Rrule Toprule Botrule\"><paragraph>47</paragraph></td><td styleCode=\"Lrule Rrule Toprule Botrule\"><paragraph>8</paragraph></td></tr><tr><td styleCode=\"Lrule Rrule Toprule Botrule\"><paragraph>Sodium decreased</paragraph></td><td styleCode=\"Lrule Rrule Toprule Botrule\"><paragraph>46</paragraph></td><td styleCode=\"Lrule Rrule Toprule Botrule\"><paragraph>6</paragraph></td></tr><tr><td styleCode=\"Lrule Rrule Toprule Botrule\"><paragraph>Albumin decreased</paragraph></td><td styleCode=\"Lrule Rrule Toprule Botrule\"><paragraph>45</paragraph></td><td styleCode=\"Lrule Rrule Toprule Botrule\"><paragraph>0</paragraph></td></tr><tr><td styleCode=\"Lrule Rrule Toprule Botrule\"><paragraph>Triglycerides increased</paragraph></td><td styleCode=\"Lrule Rrule Toprule Botrule\"><paragraph>38</paragraph></td><td styleCode=\"Lrule Rrule Toprule Botrule\"><paragraph>3.1</paragraph></td></tr><tr><td styleCode=\"Lrule Rrule Toprule Botrule\"><paragraph>Alkaline phosphatase increased</paragraph></td><td styleCode=\"Lrule Rrule Toprule Botrule\"><paragraph>35</paragraph></td><td styleCode=\"Lrule Rrule Toprule Botrule\"><paragraph>5</paragraph></td></tr><tr><td styleCode=\"Lrule Rrule Toprule Botrule\"><paragraph>Aspartate aminotransferase increased</paragraph></td><td styleCode=\"Lrule Rrule Toprule Botrule\"><paragraph>33</paragraph></td><td styleCode=\"Lrule Rrule Toprule Botrule\"><paragraph>3.9</paragraph></td></tr><tr><td styleCode=\"Lrule Rrule Toprule Botrule\"><paragraph>GGT increased</paragraph></td><td styleCode=\"Lrule Rrule Toprule Botrule\"><paragraph>34</paragraph></td><td styleCode=\"Lrule Rrule Toprule Botrule\"><paragraph>8</paragraph></td></tr><tr><td styleCode=\"Lrule Rrule Toprule Botrule\"><paragraph>Glucose increased</paragraph></td><td styleCode=\"Lrule Rrule Toprule Botrule\"><paragraph>34</paragraph></td><td styleCode=\"Lrule Rrule Toprule Botrule\"><paragraph>0</paragraph></td></tr><tr><td styleCode=\"Lrule Rrule Toprule Botrule\"><paragraph>Magnesium decreased</paragraph></td><td styleCode=\"Lrule Rrule Toprule Botrule\"><paragraph>28</paragraph></td><td styleCode=\"Lrule Rrule Toprule Botrule\"><paragraph>0.8</paragraph></td></tr><tr><td styleCode=\"Lrule Rrule Toprule Botrule\"><paragraph>Activated partial thromboplastin time prolonged</paragraph></td><td styleCode=\"Lrule Rrule Toprule Botrule\"><paragraph>22</paragraph></td><td styleCode=\"Lrule Rrule Toprule Botrule\"><paragraph>0</paragraph></td></tr><tr><td styleCode=\"Lrule Rrule Toprule Botrule\"><paragraph>Alanine aminotransferase increased</paragraph></td><td styleCode=\"Lrule Rrule Toprule Botrule\"><paragraph>20</paragraph></td><td styleCode=\"Lrule Rrule Toprule Botrule\"><paragraph>3.9</paragraph></td></tr><tr><td colspan=\"3\" styleCode=\"Lrule Rrule Toprule Botrule\"><paragraph><content styleCode=\"bold\">Hematology</content></paragraph></td></tr><tr><td styleCode=\"Lrule Rrule Toprule Botrule\"><paragraph>Lymphocytes decreased</paragraph></td><td styleCode=\"Lrule Rrule Toprule Botrule\"><paragraph>43</paragraph></td><td styleCode=\"Lrule Rrule Toprule Botrule\"><paragraph>16</paragraph></td></tr><tr><td styleCode=\"Lrule Rrule Toprule Botrule\"><paragraph>Hemoglobin decreased</paragraph></td><td styleCode=\"Lrule Rrule Toprule Botrule\"><paragraph>36</paragraph></td><td styleCode=\"Lrule Rrule Toprule Botrule\"><paragraph>4.7</paragraph></td></tr></tbody></table>"],"spl_unclassified_section":["17 PATIENT COUNSELING INFORMATION Advise the patient to read the FDA-approved patient labeling (Medication Guide). Immune-Mediated Adverse Reactions Inform patients of the risk of immune-mediated adverse reactions that may be severe or fatal, may occur after discontinuation of treatment, and may require corticosteroid treatment and interruption or discontinuation of penpulimab-kcqx [see Warnings and Precautions (5.1) ] . These reactions may include: Pneumonitis: Advise patients to contact their healthcare provider immediately for new or worsening cough, chest pain, or shortness of breath [see Warnings and Precautions (5.1) ] . Colitis: Advise patients to contact their healthcare provider immediately for diarrhea or severe abdominal pain [see Warnings and Precautions (5.1) ] . Hepatitis: Advise patients to contact their healthcare provider immediately for jaundice, severe nausea or vomiting, or easy bruising or bleeding [see Warnings and Precautions (5.1) ] . Endocrinopathies: Advise patients to contact their healthcare provider immediately for signs or symptoms of adrenal insufficiency, hypophysitis, hypothyroidism, hyperthyroidism, or Type 1 diabetes mellitus [see Warnings and Precautions (5.1) ] . Nephritis: Advise patients to contact their healthcare provider immediately for signs or symptoms of nephritis including decreased urine output, blood in urine, swelling in ankles, loss of appetite, and any other symptoms of renal dysfunction [see Warnings and Precautions (5.1) ] . Severe skin reactions: Advise patients to contact their healthcare provider immediately for any signs or symptoms of severe skin reactions, Stevens-Johnson Syndrome or Toxic Epidermal Necrolysis, including rash or any other severe skin discomfort [see Warnings and Precautions (5.1) ] . Other immune-mediated adverse reactions: o Advise patients that immune-mediated adverse reactions can occur and may involve any organ system, and to contact their healthcare provider immediately for any new or worsening signs or symptoms [see Warnings and Precautions (5.1) ] . o Advise patients of the risk of solid organ transplant rejection and other transplant (including corneal graft) rejection. Advise patients to contact their healthcare provider immediately for signs or symptoms of organ transplant rejection and other transplant (including corneal graft) rejection [see Warnings and Precautions (5.1) ]. Infusion-Related Reactions Advise patients to contact their healthcare provider immediately for signs or symptoms of infusion-related reactions [see Warnings and Precautions (5.2) ] . Complications of Allogeneic HSCT Advise patients of the risk of post-allogeneic hematopoietic stem cell transplantation complications [see Warnings and Precautions (5.3) ] . Embryo-Fetal Toxicity: Advise females of reproductive potential that penpulimab-kcqx can cause harm to a fetus and to inform their healthcare provider of a known or suspected pregnancy [see Warnings and Precautions (5.4) and Use in Specific Populations ( 8.1 , 8.3 ) ] . Advise females of reproductive potential to use effective contraception during treatment and for 4 months after the last dose of penpulimab-kcqx [see Use in Specific Populations (8.3) ] . Lactation : Advise female patients not to breastfeed while taking penpulimab-kcqx and for 4 months after the last dose [see Warnings and Precautions (5.4) and Use in Specific Populations (8.2) ] . Manufactured by: Akeso Biopharma Co., Ltd. 6 Shennong Road, Torch Development Zone, Zhongshan, Guangdong 528437, China U.S. license number xxxx"],"dosage_and_administration":["2 DOSAGE AND ADMINISTRATION Penpulimab-kcqx in combination with either cisplatin or carboplatin and gemcitabine: 200 mg intravenously over 60 minutes every 3 weeks until disease progression or a maximum of 24 months. ( 2.1 ) Penpulimab-kcqx as a single agent: 200 mg intravenously over 60 minutes every 2 weeks until disease progression or a maximum of 24 months. ( 2.2 ) Dilute prior to administration. ( 2.4 ) 2.1 Recommended Dosage of Penpulimab-kcqx in Combination with Either Cisplatin or Carboplatin and Gemcitabine – Every 3 Week Dosing First-line Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma The recommended dosage of penpulimab-kcqx is 200 mg administered as an intravenous infusion over 60 minutes every 3 weeks until disease progression or unacceptable toxicity, for a maximum of 24 months. Table 1 Order of Administration and Regimen for Penpulimab-kcqx in Combination with Either Cisplatin or Carboplatin and Gemcitabine Administer the regimen in the following order: penpulimab-kcqx first, gemcitabine second and cisplatin or carboplatin last. Drug and Dose Duration/ Timing of Treatment penpulimab-kcqx 200 mg intravenously Every 3 weeks for 6 cycles, and then every 3 weeks until unacceptable toxicity or disease progression for a maximum of 24 months gemcitabine 1000 mg/m 2 intravenously Every 3 weeks for 6 cycles cisplatin 80 mg/m 2 intravenously or carboplatin AUC 5 intravenously Every 3 weeks for 6 cycles 2.2 Recommended Dosage of Penpulimab-kcqx as a Single Agent – Every 2 Week Dosing Recurrent Metastatic Non-Keratinizing Nasopharyngeal Carcinoma The recommended dosage of penpulimab-kcqx is 200 mg administered as an intravenous infusion over 60 minutes every 2 weeks until disease progression or unacceptable toxicity, for a maximum of 24 months. 2.3 Dosage Modifications of Penpulimab-kcqx for Adverse Reactions No dose reduction for penpulimab-kcqx is recommended. In general, withhold penpulimab-kcqx for severe (Grade 3) immune-mediated adverse reactions. Permanently discontinue penpulimab-kcqx for life-threatening (Grade 4) immune-mediated adverse reactions, recurrent severe (Grade 3) immune-mediated reactions that require systemic immunosuppressive treatment, or an inability to reduce corticosteroid dose to 10 mg or less of prednisone or equivalent per day within 12 weeks of initiating steroids. Dosage modifications for penpulimab-kcqx in combination or penpulimab-kcqx as a single agent for adverse reactions that require management different from these general guidelines are summarized in Table 2 . Table 2 Recommended Dosage Modification for Adverse Reactions Adverse Reaction Severity* Dosage Modification Immune-Mediated Adverse Reactions [see Warnings and Precautions (5.1) ] Pneumonitis Grade 2 Withhold † Grade 3 or 4 Permanently discontinue Colitis Grade 2 or 3 Withhold † Grade 4 Permanently discontinue Hepatitis with no tumor involvement of the liver AST or ALT increases to more than 3 and up to 8 times ULN or Total bilirubin increases to more than 1.5 and up to 3 times ULN Withhold † AST or ALT increases to more than 8 times ULN or Total bilirubin increases to more than 3 times ULN Permanently discontinue Hepatitis with tumor involvement of the liver ‡ Baseline AST or ALT is more than 1 and up to 3 times ULN and increases to more than 5 and up to 10 times ULN or Baseline AST or ALT is more than 3 and up to 5 times ULN and increases to more than 8 and up to 10 times ULN Withhold † ALT or AST increases to more than 10 times ULN or Total bilirubin increases to more than 3 times ULN Permanently discontinue Endocrinopathies Grade 3 or 4 Withhold until clinically stable or permanently discontinue depending on severity Nephritis with Renal Dysfunction Grade 2 or 3 increased blood creatinine Withhold † Grade 4 increased blood creatinine Permanently discontinue Exfoliative Dermatologic Conditions Suspected SJS, TEN, or DRESS Withhold † Confirmed SJS, TEN, or DRESS Permanently discontinue Myocarditis Grade 2, 3, or 4 Permanently discontinue Neurological Toxicities Grade 2 Withhold † Grade 3 or 4 Permanently discontinue Other Adverse Reactions Infusion-Related Reactions [see Warnings and Precautions (5.2) ] Grade 1 or 2 Interrupt or slow the rate of infusion Grade 3 or 4 Permanently discontinue * Based on Common Terminology Criteria for Adverse Events (CTCAE), version 5.0 † Resume in patients with complete or partial resolution (Grades 0 to 1) after corticosteroid taper. Permanently discontinue if no complete or partial resolution within 12 weeks of initiating steroids or inability to reduce prednisone to 10 mg per day or less (or equivalent) within 12 weeks of initiating steroids. ‡ If AST and ALT are less than or equal to ULN at baseline, withhold or permanently discontinue penpulimab-kcqx based on recommendations for hepatitis with no liver involvement. ALT = alanine aminotransferase, AST = aspartate aminotransferase, DRESS = Drug Rash with Eosinophilia and Systemic Symptoms, SJS = Stevens Johnson Syndrome, TEN = toxic epidermal necrolysis, ULN = upper limit of normal 2.4 Preparation and Administration Preparation and Storage of Diluted Solution Inspect the solution for particulate matter and discoloration. The solution is clear to slightly opalescent, colorless to yellowish. Discard the vial if the solution is cloudy, discolored, or contains visible particles. Dilute penpulimab-kcqx injection prior to intravenous administration. Withdraw the required volume from two vials of penpulimab-kcqx and transfer into an intravenous (IV) bag containing 100 mL or less of 0.9% Sodium Chloride Injection, USP. Gently invert the bag to mix the diluted solution . Do not shake. The final concentration of the diluted solution should be between 2 mg/mL to 5 mg/mL. Discard any unused portion left in the vial. The product does not contain a preservative. Administer diluted solution immediately once prepared. If diluted solution is not administered immediately the total time from dilution to the end of the infusion should not exceed 4 hours. Store the diluted solution up to 4 hours either at room temperature 20°C to 25°C (68°F to 77°F), or refrigerated at 2°C to 8°C (36°F to 46°F). Discard after 4 hours. Do not freeze. Administration Administer diluted solution intravenously over 60 minutes through an intravenous line containing a sterile, non-pyrogenic, low-protein binding 0.2 micron to 0.22 micron in-line or add-on filter. Do not co-administer other drugs through the same infusion line."],"spl_product_data_elements":["Penpulimab kcqx Penpulimab ACETIC ACID SORBITOL SODIUM ACETATE POLYSORBATE 80 PENPULIMAB PENPULIMAB"],"dosage_forms_and_strengths":["3 DOSAGE FORMS AND STRENGTHS Injection: 100 mg/10 mL (10 mg/mL) as a clear to slightly opalescent, colorless to yellowish solution in a single-dose vial. Injection: 100 mg/10 mL (10 mg/mL) solution in a single-dose vial.(3)"],"use_in_specific_populations":["8 USE IN SPECIFIC POPULATIONS Lactation: Advise not to breastfeed ( 8.2 ) See 17 for PATIENT COUNSELING INFORMATION and Medication Guide. 8.1 Pregnancy Risk Summary Based on its mechanism of action, penpulimab-kcqx can cause fetal harm when administered to a pregnant woman [see Clinical Pharmacology (12.1) ] . There are no available data on the use of penpulimab-kcqx in pregnant women. Animal studies have demonstrated that inhibition of the PD-1/PD-L1 pathway can lead to increased risk of immune-mediated rejection of the developing fetus resulting in fetal death ( see Data ). Human immunoglobulin G (IgG) is known to cross the placental barrier; therefore, penpulimab-kcqx has the potential to be transmitted from the mother to the developing fetus. Advise women of the potential risk to a fetus. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively. Data Animal Data Animal reproduction studies have not been conducted with penpulimab-kcqx to evaluate its effect on reproduction and fetal development. A central function of the PD-1/PD-L1 pathway is to preserve pregnancy by maintaining maternal immune tolerance to the fetus. In murine models of pregnancy, blockade of PD-L1 signaling has been shown to disrupt tolerance to the fetus and to result in an increase in fetal loss; therefore, potential risks of administering penpulimab-kcqx during pregnancy include increased rates of abortion or stillbirth. As reported in the literature, there were no malformations related to the blockade of PD-1/PD-L1 signaling in the offspring of these animals; however, immune-mediated disorders occurred in PD-1 and PD-L1 knockout mice. Based on its mechanism of action, fetal exposure to penpulimab-kcqx may increase the risk of developing immune-mediated disorders or of altering the normal immune response. 8.2 Lactation Risk Summary There is no information regarding the presence of penpulimab-kcqx in human milk or its effects on the breastfed child, or on milk production. Maternal IgG is known to be present in human milk. The effects of local gastrointestinal exposure and limited systemic exposure in the breastfed child to penpulimab-kcqx are unknown. Because of the potential for serious adverse reactions in a breastfed child, advise lactating women not to breastfeed during treatment and for 4 months after the last dose of penpulimab-kcqx. 8.3 Females and Males of Reproductive Potential Penpulimab-kcqx can cause fetal harm when administered to a pregnant woman [see Use in Specific Populations (8.1) ] . Pregnancy Testing Verify pregnancy status in females of reproductive potential prior to initiating penpulimab-kcqx [see Use in Specific Populations (8.1) ]. Contraception Females Advise females of reproductive potential to use effective contraception during treatment with penpulimab-kcqx and for 4 months after the last dose. 8.4 Pediatric Use The safety and effectiveness of penpulimab-kcqx have not been established in pediatric patients [see Indications and Usage (1)] . 8.5 Geriatric Use Penpulimab-kcqx in Combination with Either Cisplatin or Carboplatin and Gemcitabine Of the 146 patients with NPC who received penpulimab-kcqx in combination with either cisplatin or carboplatin and gemcitabine, 15 (10%) were 65 years or older and 1 (0.7%) was 75 years or older. Clinical studies did not include a sufficient number of patients aged 65 years or older to determine differences in safety or effectiveness compared to younger patients [see Adverse Reactions (6) ]. Penpulimab-kcqx as a Single-Agent Of the 372 patients with NPC who received penpulimab-kcqx as a single agent, 69 (19%) were 65 years or older and 7% were 75 years and older. No overall differences in safety or effectiveness were observed between patients age <65 and those ≥ 65 years [see Adverse Reactions (6) ]."],"dosage_and_administration_table":["<table border=\"1\" cellpadding=\"0\" cellspacing=\"0\" width=\"100.0%\"><tbody><tr><td colspan=\"2\" styleCode=\"Lrule Rrule Toprule Botrule\"><paragraph>Administer the regimen in the following order: penpulimab-kcqx first, gemcitabine second and cisplatin or carboplatin last.</paragraph></td></tr><tr><td styleCode=\"Lrule Rrule Toprule Botrule\"><paragraph><content styleCode=\"bold\">Drug and Dose</content></paragraph></td><td styleCode=\"Lrule Rrule Toprule Botrule\"><paragraph><content styleCode=\"bold\">Duration/ Timing of Treatment</content></paragraph></td></tr><tr><td styleCode=\"Lrule Rrule Toprule Botrule\"><paragraph>penpulimab-kcqx 200 mg intravenously</paragraph></td><td styleCode=\"Lrule Rrule Toprule Botrule\"><paragraph>Every 3 weeks for 6 cycles, and then every 3 weeks until unacceptable toxicity or disease progression for a maximum of 24 months</paragraph></td></tr><tr><td styleCode=\"Lrule Rrule Toprule Botrule\"><paragraph>gemcitabine 1000 mg/m <sup>2</sup> intravenously </paragraph></td><td styleCode=\"Lrule Rrule Toprule Botrule\"><paragraph>Every 3 weeks for 6 cycles</paragraph></td></tr><tr><td styleCode=\"Lrule Rrule Toprule Botrule\"><paragraph>cisplatin 80 mg/m <sup>2 </sup>intravenously </paragraph><paragraph>or</paragraph><paragraph>carboplatin AUC 5 intravenously</paragraph></td><td styleCode=\"Lrule Rrule Toprule Botrule\"><paragraph>Every 3 weeks for 6 cycles</paragraph></td></tr></tbody></table>","<table border=\"1\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\" styleCode=\"TableGrid2\"><tbody><tr><td styleCode=\"Lrule Rrule Toprule Botrule\" valign=\"top\"><paragraph><content styleCode=\"bold\">Adverse Reaction</content></paragraph></td><td styleCode=\"Lrule Rrule Toprule Botrule\" valign=\"top\"><paragraph><content styleCode=\"bold\">Severity*</content></paragraph></td><td styleCode=\"Lrule Rrule Toprule Botrule\" valign=\"top\"><paragraph><content styleCode=\"bold\">Dosage Modification</content></paragraph></td></tr><tr><td colspan=\"3\" styleCode=\"Lrule Rrule Toprule Botrule\" valign=\"top\"><paragraph>Immune-Mediated Adverse Reactions <content styleCode=\"italics\">[see </content><linkHtml href=\"#La4689eda-2a41-49d0-87e4-3640ba59709b\">Warnings and Precautions (5.1)</linkHtml><content styleCode=\"italics\">]</content></paragraph></td></tr><tr><td rowspan=\"2\" styleCode=\"Lrule Rrule Toprule Botrule\" valign=\"top\"><paragraph>Pneumonitis</paragraph></td><td styleCode=\"Lrule Rrule Toprule Botrule\" valign=\"top\"><paragraph>Grade 2</paragraph></td><td styleCode=\"Lrule Rrule Toprule Botrule\" valign=\"top\"><paragraph>Withhold <sup>&#x2020;</sup></paragraph></td></tr><tr><td styleCode=\"Lrule Rrule Toprule Botrule\" valign=\"top\"><paragraph>Grade 3 or 4</paragraph></td><td styleCode=\"Lrule Rrule Toprule Botrule\" valign=\"top\"><paragraph>Permanently discontinue</paragraph></td></tr><tr><td rowspan=\"2\" styleCode=\"Lrule Rrule Toprule Botrule\" valign=\"top\"><paragraph>Colitis</paragraph></td><td styleCode=\"Lrule Rrule Toprule Botrule\" valign=\"top\"><paragraph>Grade 2 or 3</paragraph></td><td styleCode=\"Lrule Rrule Toprule Botrule\" valign=\"top\"><paragraph>Withhold <sup>&#x2020;</sup></paragraph></td></tr><tr><td styleCode=\"Lrule Rrule Toprule Botrule\" valign=\"top\"><paragraph>Grade 4</paragraph></td><td styleCode=\"Lrule Rrule Toprule Botrule\" valign=\"top\"><paragraph>Permanently discontinue</paragraph></td></tr><tr><td rowspan=\"2\" styleCode=\"Lrule Rrule Toprule Botrule\" valign=\"top\"><paragraph>Hepatitis with no tumor involvement of the liver</paragraph><paragraph/></td><td styleCode=\"Lrule Rrule Toprule Botrule\" valign=\"top\"><paragraph>AST or ALT increases to more than 3 and up to 8 times ULN</paragraph><paragraph>or</paragraph><paragraph>Total bilirubin increases to more than 1.5 and up to 3 times ULN</paragraph></td><td styleCode=\"Lrule Rrule Toprule Botrule\" valign=\"top\"><paragraph>Withhold <sup>&#x2020;</sup></paragraph></td></tr><tr><td styleCode=\"Lrule Rrule Toprule Botrule\" valign=\"top\"><paragraph>AST or ALT increases to more than 8 times ULN</paragraph><paragraph>or</paragraph><paragraph>Total bilirubin increases to more than 3 times ULN</paragraph></td><td styleCode=\"Lrule Rrule Toprule Botrule\" valign=\"top\"><paragraph>Permanently discontinue</paragraph></td></tr><tr><td rowspan=\"2\" styleCode=\"Lrule Rrule Toprule Botrule\" valign=\"top\"><paragraph>Hepatitis with tumor involvement of the liver <sup>&#x2021;</sup></paragraph></td><td styleCode=\"Lrule Rrule Toprule Botrule\" valign=\"top\"><paragraph>Baseline AST or ALT is more than 1 and up to 3 times ULN and increases to more than 5 and up to 10 times ULN or</paragraph><paragraph>Baseline AST or ALT is more than 3 and up to 5 times ULN and increases to more than 8 and up to 10 times ULN</paragraph></td><td styleCode=\"Lrule Rrule Toprule Botrule\" valign=\"top\"><paragraph>Withhold <sup>&#x2020;</sup></paragraph></td></tr><tr><td styleCode=\"Lrule Rrule Toprule Botrule\" valign=\"top\"><paragraph>ALT or AST increases to more than 10 times ULN</paragraph><paragraph>or</paragraph><paragraph>Total bilirubin increases to more than 3 times ULN</paragraph></td><td styleCode=\"Lrule Rrule Toprule Botrule\" valign=\"top\"><paragraph>Permanently discontinue</paragraph></td></tr><tr><td styleCode=\"Lrule Rrule Toprule Botrule\" valign=\"top\"><paragraph>Endocrinopathies</paragraph></td><td styleCode=\"Lrule Rrule Toprule Botrule\" valign=\"top\"><paragraph>Grade 3 or 4</paragraph></td><td styleCode=\"Lrule Rrule Toprule Botrule\" valign=\"top\"><paragraph>Withhold until clinically stable or permanently discontinue depending on severity</paragraph></td></tr><tr><td rowspan=\"2\" styleCode=\"Lrule Rrule Toprule Botrule\" valign=\"top\"><paragraph>Nephritis with Renal Dysfunction</paragraph></td><td styleCode=\"Lrule Rrule Toprule Botrule\" valign=\"top\"><paragraph>Grade 2 or 3 increased blood creatinine</paragraph></td><td styleCode=\"Lrule Rrule Toprule Botrule\" valign=\"top\"><paragraph>Withhold <sup>&#x2020;</sup></paragraph></td></tr><tr><td styleCode=\"Lrule Rrule Toprule Botrule\" valign=\"top\"><paragraph>Grade 4 increased blood creatinine</paragraph></td><td styleCode=\"Lrule Rrule Toprule Botrule\" valign=\"top\"><paragraph>Permanently discontinue</paragraph></td></tr><tr><td rowspan=\"2\" styleCode=\"Lrule Rrule Toprule Botrule\" valign=\"top\"><paragraph>Exfoliative Dermatologic Conditions</paragraph></td><td styleCode=\"Lrule Rrule Toprule Botrule\" valign=\"top\"><paragraph>Suspected SJS, TEN, or DRESS</paragraph></td><td styleCode=\"Lrule Rrule Toprule Botrule\" valign=\"top\"><paragraph>Withhold <sup>&#x2020;</sup></paragraph></td></tr><tr><td styleCode=\"Lrule Rrule Toprule Botrule\" valign=\"top\"><paragraph>Confirmed SJS, TEN, or DRESS</paragraph></td><td styleCode=\"Lrule Rrule Toprule Botrule\" valign=\"top\"><paragraph>Permanently discontinue</paragraph></td></tr><tr><td styleCode=\"Lrule Rrule Toprule Botrule\" valign=\"top\"><paragraph>Myocarditis</paragraph></td><td styleCode=\"Lrule Rrule Toprule Botrule\" valign=\"top\"><paragraph>Grade 2, 3, or 4</paragraph></td><td styleCode=\"Lrule Rrule Toprule Botrule\" valign=\"top\"><paragraph>Permanently discontinue</paragraph></td></tr><tr><td rowspan=\"2\" styleCode=\"Lrule Rrule Toprule Botrule\" valign=\"top\"><paragraph>Neurological Toxicities</paragraph></td><td styleCode=\"Lrule Rrule Toprule Botrule\" valign=\"top\"><paragraph>Grade 2</paragraph></td><td styleCode=\"Lrule Rrule Toprule Botrule\" valign=\"top\"><paragraph>Withhold <sup>&#x2020;</sup></paragraph></td></tr><tr><td styleCode=\"Lrule Rrule Toprule Botrule\" valign=\"top\"><paragraph>Grade 3 or 4</paragraph></td><td styleCode=\"Lrule Rrule Toprule Botrule\" valign=\"top\"><paragraph>Permanently discontinue</paragraph></td></tr><tr><td colspan=\"3\" styleCode=\"Lrule Rrule Toprule Botrule\" valign=\"top\"><paragraph>Other Adverse Reactions</paragraph></td></tr><tr><td rowspan=\"2\" styleCode=\"Lrule Rrule Toprule Botrule\" valign=\"top\"><paragraph>Infusion-Related Reactions <content styleCode=\"italics\">[see</content><linkHtml href=\"#L7fe20d0c-6805-4d9b-9ad3-db2a389f1123\">Warnings and Precautions (5.2) </linkHtml><content styleCode=\"italics\">]</content></paragraph></td><td styleCode=\"Lrule Rrule Toprule Botrule\" valign=\"top\"><paragraph>Grade 1 or 2</paragraph></td><td styleCode=\"Lrule Rrule Toprule Botrule\" valign=\"top\"><paragraph>Interrupt or slow the rate of infusion</paragraph></td></tr><tr><td styleCode=\"Lrule Rrule Toprule Botrule\" valign=\"top\"><paragraph>Grade 3 or 4</paragraph></td><td styleCode=\"Lrule Rrule Toprule Botrule\" valign=\"top\"><paragraph>Permanently discontinue</paragraph></td></tr></tbody></table>"],"package_label_principal_display_panel":["carton label vial label"]},"tags":[{"label":"Monoclonal Antibody","category":"modality"},{"label":"Pd-1","category":"target"},{"label":"Intravenous","category":"route"},{"label":"Injectable","category":"form"},{"label":"Active","category":"status"},{"label":"Recurrent or Metastatic Non-Keratinizing Nasopharyngeal Carcinoma","category":"indication"},{"label":"Metastatic Non-Keratinizing Nasopharyngeal Carcinoma with disease progression on or after platinum-based chemotherapy and at least one other prior line of therapy","category":"indication"},{"label":"Akeso Biopharma","category":"company"},{"label":"Approved 2020s","category":"decade"}],"phase":"marketed","safety":{"boxedWarnings":[],"safetySignals":[{"date":"","signal":"MYELOSUPPRESSION","source":"FDA FAERS","actionTaken":"10 reports"},{"date":"","signal":"ANAEMIA","source":"FDA FAERS","actionTaken":"8 reports"},{"date":"","signal":"DIARRHOEA","source":"FDA FAERS","actionTaken":"7 reports"},{"date":"","signal":"THROMBOCYTOPENIA","source":"FDA FAERS","actionTaken":"7 reports"},{"date":"","signal":"HYPOTHYROIDISM","source":"FDA FAERS","actionTaken":"6 reports"},{"date":"","signal":"LEUKOPENIA","source":"FDA FAERS","actionTaken":"6 reports"},{"date":"","signal":"RASH","source":"FDA FAERS","actionTaken":"6 reports"},{"date":"","signal":"VOMITING","source":"FDA FAERS","actionTaken":"6 reports"},{"date":"","signal":"ALANINE AMINOTRANSFERASE INCREASED","source":"FDA FAERS","actionTaken":"5 reports"},{"date":"","signal":"ASPARTATE AMINOTRANSFERASE INCREASED","source":"FDA FAERS","actionTaken":"5 reports"}],"commonSideEffects":[{"effect":"Nausea","drugRate":"58%","severity":"serious","_validated":true},{"effect":"Vomiting","drugRate":"55%","severity":"serious","_validated":true},{"effect":"Hypothyroidism","drugRate":"45%","severity":"serious","_validated":true},{"effect":"Constipation","drugRate":"41%","severity":"common","_validated":true},{"effect":"Decreased appetite","drugRate":"36%","severity":"common","_validated":true},{"effect":"Decreased weight","drugRate":"26%","severity":"common","_validated":true},{"effect":"Cough","drugRate":"25%","severity":"common","_validated":true},{"effect":"COVID-19 infection","drugRate":"25%","severity":"common","_validated":true},{"effect":"Fatigue","drugRate":"25%","severity":"common","_validated":true},{"effect":"Rash","drugRate":"24%","severity":"common","_validated":true},{"effect":"Pyrexia","drugRate":"21%","severity":"common","_validated":true},{"effect":"Anemia","drugRate":"25%","severity":"serious","_validated":true},{"effect":"Thrombocytopenia","drugRate":"19%","severity":"serious","_validated":true},{"effect":"Decreased neutrophils","drugRate":"14%","severity":"serious","_validated":true},{"effect":"Decreased white blood cells","drugRate":"12%","severity":"serious","_validated":true},{"effect":"Myelosuppression","drugRate":"3.4%","severity":"mild","_validated":true},{"effect":"Decreased sodium","drugRate":"2.7%","severity":"mild","_validated":true},{"effect":"Pneumonia","drugRate":"2.1%","severity":"mild","_validated":true},{"effect":"Acute myocardial infarction","drugRate":"reported","severity":"unknown"},{"effect":"Acute kidney injury","drugRate":"reported","severity":"unknown"},{"effect":"Brain edema","drugRate":"reported","severity":"unknown"},{"effect":"Diabetic ketoacidosis","drugRate":"reported","severity":"unknown"},{"effect":"Increased potassium","drugRate":"reported","severity":"unknown"},{"effect":"Increased lipase","drugRate":"reported","severity":"unknown"}],"contraindications":[],"specialPopulations":{"Lactation":"Advise not to breastfeed","Pregnancy":"Based on its mechanism of action, penpulimab-kcqx can cause fetal harm when administered to a pregnant woman. There are no available data on the use of penpulimab-kcqx in pregnant women. Animal studies have demonstrated that inhibition of the PD-1/PD-L1 pathway can lead to increased risk of immune-mediated rejection of the developing fetus resulting in fetal death. Human immunoglobulin G (IgG) is known to cross the placental barrier; therefore, penpulimab-kcqx has the potential to be transmitted from the mother to the developing fetus. Advise women of the potential risk to a fetus. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively."}},"trials":[],"aliases":[],"company":"Akeso Biopharma","patents":[],"pricing":[],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=PENPULIMAB","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T00:50:49.910841+00:00"},"timeline":{"url":"https://en.wikipedia.org/wiki/Penpulimab","method":"deterministic","source":"Wikipedia","rawText":"","confidence":0.8,"sourceType":"wikipedia","retrievedAt":"2026-04-20T00:50:57.103599+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T00:50:55.467892+00:00"},"regulatory.us":{"url":"","method":"api_direct","source":"FDA Drugs@FDA","rawText":"","confidence":1,"sourceType":"fda_drugsfda","retrievedAt":"2026-04-20T00:50:45.951377+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=PENPULIMAB","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T00:50:55.962763+00:00"},"administration.route":{"url":"","method":"deterministic","source":"FDA Label","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T00:50:45.498138+00:00"},"safety.boxedWarnings":{"url":"","method":"deterministic","source":"FDA Label (no boxed warning)","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T00:50:45.498167+00:00"},"safety.safetySignals":{"url":"https://api.fda.gov/drug/event.json","method":"api_direct","source":"FDA FAERS","rawText":"","confidence":1,"sourceType":"fda_faers","retrievedAt":"2026-04-20T00:50:57.610507+00:00"},"mechanism.target_chembl":{"url":"","method":"api_direct","source":"ChEMBL mechanism: Programmed cell death protein 1 inhibitor","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T00:50:56.999001+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL4297571/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T00:50:56.657836+00:00"},"regulatory.fda_application":{"url":"","method":"deterministic","source":"FDA Label","rawText":"BLA761258","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T00:50:45.498171+00:00"}},"allNames":"penpulimab kcqx","offLabel":[],"synonyms":["Penpulimab kcqx"],"timeline":[{"date":"20250423","type":"positive","source":"OpenFDA","milestone":"FDA approval (Akeso Biopharma)"}],"approvals":[{"date":"20250423","orphan":false,"company":"AKESO BIOPHARMA","regulator":"FDA"}],"brandName":"Penpulimab kcqx","ecosystem":[],"mechanism":{"target":"Pd-1","modality":"Monoclonal Antibody","explanation":"Binding of the PD-1 ligands, PD-L1 and PD-L2, to the PD-1 receptor found on T cells, inhibits T-cell proliferation and cytokine production. Upregulation of PD-1 ligands occurs in some tumors and signaling through this pathway can contribute to inhibition of active T-cell immune surveillance of tumors. Penpulimab-kcqx injection is a humanized IgG1 monoclonal antibody that binds to PD-1 and blocks its interaction with PD-L1 and PD-L2, releasing PD-1 pathway-mediated inhibition of the immune response, including the anti-tumor immune response. In murine tumor models, blocking PD-1 activity resulted in decreased tumor growth.","oneSentence":"Penpulimab works by binding to the PD-1 protein on immune cells, blocking its interaction with the PD-L1 protein on cancer cells and allowing the immune system to attack the cancer.","technicalDetail":"Penpulimab is a monoclonal antibody that selectively binds to the PD-1 protein on the surface of immune cells, specifically T cells and natural killer cells, thereby preventing its interaction with the PD-L1 protein on cancer cells and promoting an anti-tumor immune response."},"_wikipedia":{"url":"https://en.wikipedia.org/wiki/Penpulimab","title":"Penpulimab","extract":"Penpulimab is a humanized monoclonal antibody used for the treatment of cancer. It targets the programmed cell death protein 1 (PD-1) receptor. It is developed by Akeso.","wiki_history":"== History ==\nThe efficacy of penpulimab with cisplatin or carboplatin and gemcitabine was evaluated in study AK105-304 (NCT04974398), a randomized, double-blind, multi-center trial in 291 participants with recurrent or metastatic nasopharyngeal carcinoma who had not received previous systemic chemotherapy for recurrent or metastatic disease. Participants were randomized (1:1) to receive either penpulimab with cisplatin or carboplatin and gemcitabine, followed by penpulimab, or placebo with cisplatin or carboplatin and gemcitabine, followed by placebo.\n\nThe efficacy of single-agent penpulimab was evaluated in study AK105-202 (NCT03866967), an open-label, multi-center, single-arm trial conducted in a single country. The trial included a total of 125 participants with unresectable or metastatic non-keratinizing nasopharyngeal carcinoma who had disease progression after platinum-based chemotherapy and at least one other line of therapy. Participants received penpulimab until disease progression or unacceptable toxicity, for a maximum of 24 months.","wiki_society_and_culture":"== Society and culture ==\n=== Legal status ===\nIn March 2025, penpulimab, was approved by the National Medical Products Administration in China for the first-line treatment of recurrent or metastatic nasopharyngeal cancer in combination with chemotherapy.\n\nIn April 2025, the US Food and Drug Administration (FDA) approved penpulimab-kcqx with cisplatin or carboplatin and gemcitabine for the first-line treatment of adults with recurrent or metastatic non-keratinizing nasopharyngeal carcinoma.\n\nPenpulimab is sold under the brand name 安尼可 (Anike) in China. non-small-cell lung cancer, and other solid tumors."},"commercial":{"launchDate":"2025","_launchSource":"OpenFDA (20250423, AKESO BIOPHARMA)"},"references":[{"id":1,"url":"https://api.fda.gov/drug/label.json?search=openfda.generic_name:\"PENPULIMAB\"","fields":["mechanism","indications","adverse_reactions","contraindications","warnings","dosage"],"source":"OpenFDA Label"},{"id":2,"url":"https://api.fda.gov/drug/drugsfda.json?search=openfda.generic_name:\"PENPULIMAB\"","fields":["approvals","company"],"source":"OpenFDA Drugs@FDA"},{"id":3,"url":"https://clinicaltrials.gov/search?intr=penpulimab","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":4,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=penpulimab","fields":["publications"],"source":"PubMed/NCBI"},{"id":5,"url":"https://en.wikipedia.org/wiki/Penpulimab","fields":["history","overview"],"source":"Wikipedia"}],"_enrichedAt":"2026-03-31T10:25:33.961035","_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T00:51:00.812171+00:00","fieldsConflicting":0,"overallConfidence":0.95},"biosimilars":[],"competitors":[],"genericName":"penpulimab","indications":{"approved":[{"name":"Recurrent or Metastatic Non-Keratinizing Nasopharyngeal Carcinoma","source":"OpenFDA Label","regulator":"FDA"},{"name":"Metastatic Non-Keratinizing Nasopharyngeal Carcinoma with disease progression on or after platinum-based chemotherapy and at least one other prior line of therapy","source":"OpenFDA Label","regulator":"FDA"}],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[],"trialDetails":[{"nctId":"NCT03866967","phase":"PHASE2","title":"A Study of Anti-PD-1 AK105 in Patients With Metastatic Nasopharyngeal Carcinoma","status":"COMPLETED","sponsor":"Akeso","isPivotal":true,"startDate":"2019-03-27","conditions":["Nasopharyngeal Carcinoma"],"enrollment":130,"completionDate":"2024-03-22"},{"nctId":"NCT06821503","phase":"PHASE1,PHASE2","title":"Clinical Study Evaluating the Safety, Tolerability, and Preliminary Efficacy of LM-108 ± Penpulimab+Chemotherapy in Advanced Solid Tumors - Cohort C","status":"RECRUITING","sponsor":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","startDate":"2025-04-11","conditions":["Advanced Pancreatic Cancer"],"enrollment":72,"completionDate":"2028-12"},{"nctId":"NCT07419880","phase":"PHASE2","title":"Re-challenge Immunotherapy With Cromolyn, TQB2102, and Panpulimab in Immune-Refractory Triple Negative Breast Cancer","status":"NOT_YET_RECRUITING","sponsor":"Fudan University","startDate":"2026-01-30","conditions":["Triple -Negative Breast Cancer"],"enrollment":46,"completionDate":"2027-04-30"},{"nctId":"NCT07392320","phase":"PHASE2","title":"A Phase II Trial Comparing Immunotherapy Versus Capecitabine Maintenance After Chemo-chemoradiotherapy for High-risk Nasopharyngeal Carcinoma","status":"RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2026-02-04","conditions":["Nasopharangeal Cancer"],"enrollment":142,"completionDate":"2033-02-04"},{"nctId":"NCT07387081","phase":"PHASE2","title":"Phase II Study of LM-24C5","status":"RECRUITING","sponsor":"LaNova Medicines Limited","startDate":"2025-12-15","conditions":["Advanced Solid Tumor Cancer"],"enrollment":130,"completionDate":"2028-10-25"},{"nctId":"NCT07381075","phase":"PHASE2","title":"A Phase II Clinical Trial of Anti-EGFR Antibody-drug Conjugate (ADC) Combined With or Without Immune Checkpoint Inhibitors in the Neoadjuvant Treatment of Resectable Locally Advanced Head and Neck Squamous Cell Carcinoma","status":"NOT_YET_RECRUITING","sponsor":"West China Hospital","startDate":"2026-02-01","conditions":["Head and Neck Squamous Cell Carcinoma"],"enrollment":120,"completionDate":"2029-06-01"},{"nctId":"NCT05807880","phase":"PHASE2","title":"Anlotinib, Penpulimab and Capecitabine in Recurrent/Metastatic Nasopharyngeal Carcinoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2023-09-01","conditions":["Nasopharyngeal Neoplasms"],"enrollment":59,"completionDate":"2026-07-01"},{"nctId":"NCT05001971","phase":"PHASE2","title":"Anlotinib Plus Penpulimab as Second-line Treatment for Patients With Small Cell Lung Cancer After Failure of Platinum-based Chemotherapy","status":"COMPLETED","sponsor":"Hunan Cancer Hospital","startDate":"2021-01-30","conditions":["Small Cell Lung Cancer"],"enrollment":65,"completionDate":"2025-04-15"},{"nctId":"NCT06825494","phase":"PHASE1,PHASE2","title":"Clinical Studies for the Treatment of Advanced Solid Tumors","status":"RECRUITING","sponsor":"Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.","startDate":"2025-04-08","conditions":["Advanced Solid Tumor"],"enrollment":194,"completionDate":"2026-09"},{"nctId":"NCT06320080","phase":"PHASE1","title":"Clinical Study of TQB2223 Injection Combined With AK105 Injection in the Treatment of Advanced Hepatocellular Carcinoma.","status":"TERMINATED","sponsor":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","startDate":"2024-05-30","conditions":["Advanced Hepatocellular Carcinoma"],"enrollment":22,"completionDate":"2025-11-03"},{"nctId":"NCT06788002","phase":"PHASE2","title":"LDRT and Chemoimmunotherapy in NPC With Liver Metastasis","status":"RECRUITING","sponsor":"Hunan Cancer Hospital","startDate":"2025-01-14","conditions":["Nasopharyngeal Cancinoma (NPC)"],"enrollment":26,"completionDate":"2027-06-30"},{"nctId":"NCT05576480","phase":"PHASE2","title":"SCRT Sequential Penpulimab in Combination With CAPEOX in the Neoadjuvant Treatment of MSS Locally Advanced Rectal Cancer","status":"RECRUITING","sponsor":"Ruijin Hospital","startDate":"2023-02-06","conditions":["Rectal Cancer","Locally Advanced"],"enrollment":55,"completionDate":"2026-12"},{"nctId":"NCT05975645","phase":"PHASE1","title":"A Clinical Study of TQB2618 Injection Combined With Penpulimab Injection and Anlotinib Hydrochloride Capsules for First-line Treatment of Advanced Hepatocellular Carcinoma (HCC).","status":"TERMINATED","sponsor":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","startDate":"2023-08-15","conditions":["Advanced Hepatocellular Carcinoma"],"enrollment":29,"completionDate":"2025-06-04"},{"nctId":"NCT06767800","phase":"PHASE2","title":"A Clinical Trial Evaluating TQB2102 for Injection in Combination With Behmosubaisumab/Payamprolizumab With or Without Chemotherapy in Unresectable Locally Advanced, Recurrent, or Metastatic Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastroesophageal Adenocarcinoma","status":"RECRUITING","sponsor":"Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.","startDate":"2024-11-21","conditions":["Gastroesophageal Adenocarcinoma"],"enrollment":204,"completionDate":"2027-09"},{"nctId":"NCT07086326","phase":"PHASE2","title":"A Phase II Randomized Trial of Neoadjuvant Ivonescimab or Penpulimab Plus Chemotherapy in Resectable NSCLC","status":"NOT_YET_RECRUITING","sponsor":"Yang Fan, MD","startDate":"2025-07-31","conditions":["NSCLC","Neoadjuvant Therapy","Immunotherapy","AK112","Bispecific Antibody"],"enrollment":164,"completionDate":"2027-12-30"},{"nctId":"NCT07075419","phase":"PHASE1,PHASE2","title":"JDB153 Combined With Penpulimab for Hepatocellular Carcinoma After Standard Treatment Failure","status":"NOT_YET_RECRUITING","sponsor":"West China Hospital","startDate":"2025-08-01","conditions":["Refractory Hepatocellular Carcinoma"],"enrollment":10,"completionDate":"2027-08-01"},{"nctId":"NCT05834543","phase":"PHASE1,PHASE2","title":"Clinical Trial to Evaluate the Safety and Effectiveness of TQB2618 Injection Combined Therapy in Patients With Advanced Esophageal Squamous Cell Carcinoma","status":"TERMINATED","sponsor":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","startDate":"2023-05-26","conditions":["Advanced Esophageal Squamous Cell Carcinoma"],"enrollment":34,"completionDate":"2025-03-03"},{"nctId":"NCT07035860","phase":"","title":"Efficacy and Safety of Chemoimmunotherapy and Carbon Ion Radiotherapy in Unresectable Locally Advanced Non-small Cell Lung Cancer","status":"NOT_YET_RECRUITING","sponsor":"Ji Yongling","startDate":"2025-06-16","conditions":["Carbon Ion Radiotheray"],"enrollment":34,"completionDate":"2028-06-15"},{"nctId":"NCT06943820","phase":"PHASE1,PHASE2","title":"AK129 Combination Therapy for Advanced Solid Tumors","status":"RECRUITING","sponsor":"Akeso","startDate":"2025-05-21","conditions":["Non-small Cell Lung Cancer Stage IIIB/IV","Head and Neck Squamous Cell Carcinoma (HNSCC)","Colorectal Adenocarcinoma","Advanced Solid Tumors"],"enrollment":230,"completionDate":"2028-05"},{"nctId":"NCT06429397","phase":"PHASE2","title":"Anlotinib Combined With Benmelstobart for Advanced Pheochromocytoma","status":"NOT_YET_RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2025-05-01","conditions":["Pheochromocytoma"],"enrollment":22,"completionDate":"2027-05-28"},{"nctId":"NCT04974398","phase":"PHASE3","title":"A Study of Penpulimab (AK105) in the First-line Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Akeso","isPivotal":true,"startDate":"2021-08-16","conditions":["Nasopharyngeal Carcinoma"],"enrollment":296,"completionDate":"2026-12-23"},{"nctId":"NCT06886347","phase":"PHASE1","title":"Metastatic Nasopharyngeal Carcinoma","status":"RECRUITING","sponsor":"Chen Xiaozhong","startDate":"2023-07-07","conditions":["Metastatic Nasopharyngeal Carcinoma"],"enrollment":47,"completionDate":"2026-04-01"},{"nctId":"NCT04736810","phase":"PHASE2","title":"A Study of Penpulimab Combination Therapy in Patients With Advanced Nasopharyngeal Carcinoma","status":"COMPLETED","sponsor":"Akeso","startDate":"2021-02-25","conditions":["Nasopharyngeal Carcinoma"],"enrollment":28,"completionDate":"2023-12-18"},{"nctId":"NCT06853769","phase":"EARLY_PHASE1","title":"Neoadjuvant Therapy for Locally Advanced Rectal Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"The First Affiliated Hospital with Nanjing Medical University","startDate":"2024-09-01","conditions":["Colorectal Cancer"],"enrollment":48,"completionDate":"2027-08-01"},{"nctId":"NCT05214222","phase":"PHASE2","title":"Penpulimab Plus Chemotherapy With/Without Anlotinib for Patients With Advanced Esophageal Squamous Cell Carcinoma","status":"RECRUITING","sponsor":"Nanfang Hospital, Southern Medical University","startDate":"2022-09-02","conditions":["Advanced Esophageal Squamous Cell Carcinoma"],"enrollment":100,"completionDate":"2028-09-02"},{"nctId":"NCT06444009","phase":"PHASE2","title":"A Phase II Study of Neoadjuvant Immunotherapy in Combination With Chemotherapy in Locally Advanced Head and Neck Squamous Cell Carcinoma","status":"RECRUITING","sponsor":"Lei Liu","startDate":"2024-07-01","conditions":["Head and Neck Squamous Cell Carcinoma"],"enrollment":90,"completionDate":"2027-12-01"},{"nctId":"NCT05772455","phase":"PHASE1","title":"A Study of XZB-0004 in Patients With Solid Tumors","status":"RECRUITING","sponsor":"Xuanzhu Biopharmaceutical Co., Ltd.","startDate":"2023-03-24","conditions":["Advanced Solid Tumor","NSCLC"],"enrollment":128,"completionDate":"2027-02"},{"nctId":"NCT06649656","phase":"PHASE1","title":"A Multicenter, Open Label Phase I Clinical Trial Evaluating the Safety and Pharmacokinetics of TQB2252 Injection in Subjects With Advanced Malignant Tumors","status":"NOT_YET_RECRUITING","sponsor":"Chia Tai Tianqing Pharmaceutical (Guangzhou) Co., Ltd.","startDate":"2024-11","conditions":["Advanced Cancers"],"enrollment":100,"completionDate":"2026-12"},{"nctId":"NCT06586242","phase":"PHASE2","title":"Efficacy and Safety of Penpulimab Combined With Anlotinib and Chemotherapy","status":"RECRUITING","sponsor":"Xijing Hospital","startDate":"2023-04-03","conditions":["Esophageal Cancer"],"enrollment":194,"completionDate":"2036-04"},{"nctId":"NCT05949931","phase":"PHASE2","title":"Pianzumab Combined With AVD Regimen in the Treatment of Newly-diagnosed Advanced Classic Hodgkin Lymphoma","status":"RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2023-10-01","conditions":["Classic Hodgkin Lymphoma"],"enrollment":108,"completionDate":"2027-12"},{"nctId":"NCT06297642","phase":"PHASE1","title":"TQB2928 Injection Combined With Penpulimab in Treatment of Advanced Malignant Tumors.","status":"TERMINATED","sponsor":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","startDate":"2024-05-24","conditions":["Advanced Malignant Neoplasm"],"enrollment":3,"completionDate":"2024-07-31"},{"nctId":"NCT06516978","phase":"PHASE2","title":"A Study Comparing the Efficacy and Safety of Pola-RCHP-X Versus RCHOP-X and Pola-RCHP in Previously Untreated Patients With DLBCL","status":"NOT_YET_RECRUITING","sponsor":"The First Affiliated Hospital with Nanjing Medical University","startDate":"2024-10-01","conditions":["Diffuse Large B Cell Lymphoma"],"enrollment":528,"completionDate":"2029-04-01"},{"nctId":"NCT05193617","phase":"PHASE2","title":"Penpulimab Combined With GP ± Anlotinib as Neoadjuvant Therapy in Locoregionally Advanced Nasopharyngeal Carcinoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2022-01-20","conditions":["Nasopharyngeal Carcinoma"],"enrollment":104,"completionDate":"2027-01-01"},{"nctId":"NCT06500091","phase":"PHASE2","title":"TQB2916 Injection Combined With Chemotherapy or Penpulimab Injection in the Treatment of Solid Tumors","status":"NOT_YET_RECRUITING","sponsor":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","startDate":"2024-07","conditions":["Soft Tissue Sarcoma","Melanoma"],"enrollment":54,"completionDate":"2026-12"},{"nctId":"NCT05229003","phase":"PHASE2","title":"Irinotecan Plus Anlotinib or Further in Combination With Penpulimab for Second-line Treatment of mCRC","status":"RECRUITING","sponsor":"Fudan University","startDate":"2022-03-09","conditions":["Metastatic Colorectal Cancer"],"enrollment":44,"completionDate":"2025-12-31"},{"nctId":"NCT05493995","phase":"PHASE2","title":"A Study of Penpulimab and Anlotinib Plus Nab-paclitaxel and Gemcitabine for Metastatic Pancreatic Cancer.","status":"COMPLETED","sponsor":"The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School","startDate":"2022-07-21","conditions":["Pancreatic Neoplasms"],"enrollment":66,"completionDate":"2024-05-01"},{"nctId":"NCT06341530","phase":"PHASE2","title":"Anlotinib Combined With Penpulimab as Front-line Treatment in Advanced Non-small Cell Lung Cancer","status":"RECRUITING","sponsor":"The First Affiliated Hospital of Zhengzhou University","startDate":"2024-01-31","conditions":["Non-small Cell Lung Cancer"],"enrollment":33,"completionDate":"2025-12-31"},{"nctId":"NCT06032052","phase":"PHASE2","title":"Single-drug Chemotherapy Plus Immunotherapy in Metastatic Non-small Cell Lung Cancer Elderly Patients","status":"RECRUITING","sponsor":"Hubei Cancer Hospital","startDate":"2024-02-01","conditions":["Elderly Patients","Metastatic Lung Cancer"],"enrollment":49,"completionDate":"2027-09"},{"nctId":"NCT05894421","phase":"PHASE1","title":"TQB2223 Injection in Combination With Penpulimab in Patients With Advanced Cancers","status":"RECRUITING","sponsor":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","startDate":"2023-06-06","conditions":["Advanced Cancer"],"enrollment":92,"completionDate":"2026-01"},{"nctId":"NCT06010901","phase":"PHASE1","title":"A Clinical Study of TQB2618 Injection Monotherapy and Combination Regimen (With Penpulimab Injection ±Anlotinib Hydrochloride Capsules) in the Four or Later Lines of Treatment of Advanced Colorectal Cancer.","status":"UNKNOWN","sponsor":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","startDate":"2024-01-13","conditions":["Colorectal Cancer"],"enrollment":75,"completionDate":"2025-07"},{"nctId":"NCT05028504","phase":"PHASE2","title":"A Phase II Study of Anlotinib Combined With Penpulimab in Subjects With Gynecological Cancer","status":"UNKNOWN","sponsor":"Sichuan Cancer Hospital and Research Institute","startDate":"2022-05-10","conditions":["Gynecological Cancer"],"enrollment":86,"completionDate":"2025-12-31"},{"nctId":"NCT05494060","phase":"PHASE2","title":"XELOX Combined With Anlotinib and Penpulimab vs XELOX as Adjuvant Therapy in ctDNA Positive Gastric and Esophagogastric Junction Adenocarcinoma","status":"RECRUITING","sponsor":"The First Affiliated Hospital with Nanjing Medical University","startDate":"2022-03-16","conditions":["Carcinoma","Gastrointestinal Diseases","Stomach Cancer","Gastroesophageal-junction Cancer","Digestive System Diseases","Gastric Cancer","Gastrointestinal Neoplasms"],"enrollment":80,"completionDate":"2027-02"},{"nctId":"NCT06114225","phase":"PHASE2","title":"Pulmonary Resectable Osteosarcoma Treated by Metastasectomy and Pre-operative Immunotherapy and Stereotactic Body Radiotherapy (PROMIS): a Prospective Clinical Trial","status":"RECRUITING","sponsor":"Ruijin Hospital","startDate":"2023-06-01","conditions":["Osteosarcoma"],"enrollment":43,"completionDate":"2026-12-30"},{"nctId":"NCT05260671","phase":"PHASE2","title":"Penpulimab in Combination With Cetuximab as First-line Treatment in R/M SCCHN","status":"RECRUITING","sponsor":"Eye & ENT Hospital of Fudan University","startDate":"2022-01-25","conditions":["Head and Neck Neoplasms","Recurrent Disease","Metastatic Cancer"],"enrollment":48,"completionDate":"2026-12-25"},{"nctId":"NCT06081673","phase":"PHASE2","title":"Penpulimab Combined With Chemotherapy for Neoadjuvant and Adjuvant Therapy in Patients With Resectable HNSCC","status":"RECRUITING","sponsor":"Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University","startDate":"2023-10-30","conditions":["Head and Neck Squamous Cell Carcinoma"],"enrollment":72,"completionDate":"2026-10-30"},{"nctId":"NCT06062563","phase":"NA","title":"Study of Anlotinib in Patients With Radioiodine Refractory Differentiated Thyroid Cancer","status":"UNKNOWN","sponsor":"Peking Union Medical College Hospital","startDate":"2023-11-11","conditions":["Locally Advanced or Metastatic Radioiodine-refractory Differentiated Thyroid Carcinoma"],"enrollment":10,"completionDate":"2025-08-20"},{"nctId":"NCT06051851","phase":"PHASE2","title":"Penpulimab Combined With Anlotinib and Nab-paclitaxel Plus Gemcitabine as First-line Treatment for Advanced Metastatic Pancreatic Cancer","status":"RECRUITING","sponsor":"The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School","startDate":"2023-07-01","conditions":["Pancreatic Adenocarcinoma Metastatic"],"enrollment":177,"completionDate":"2026-07-01"},{"nctId":"NCT06048315","phase":"PHASE3","title":"A Single Center, Single Arm Clinical Study on the Treatment of Advanced Non-small Cell Lung Cancer With Positive EGFR Sensitive Mutations and Failed EGFR TKIs With the Combination of Enrotinib and Paclitaxel Monoclonal Antibody","status":"NOT_YET_RECRUITING","sponsor":"Degan Lu","startDate":"2023-09","conditions":["Lung Cancer","TKI Resistance","EGFR Sensitive Mutation","Anlotinib","Pianzumab"],"enrollment":52,"completionDate":"2026-09"},{"nctId":"NCT05783921","phase":"PHASE1,PHASE2","title":"A Clinical Trial of TQB2618 Injection Combined With Penpulimab Injection and Chemotherapy Versus Penpulimab Injection Combined With Chemotherapy in First-line Treatment of Relapsed/Metastatic Head and Neck Squamous Cell Carcinoma","status":"UNKNOWN","sponsor":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","startDate":"2023-05-23","conditions":["Recurrent Squamous Cell Carcinoma of the Head and Neck","Metastatic Squamous Cell Carcinoma"],"enrollment":60,"completionDate":"2025-01"},{"nctId":"NCT05885399","phase":"PHASE2","title":"The Efficacy and Safety of Penpulimab in the Treatment of Metastatic PPGL Patients Who Fail to Other Systemic Treatment","status":"UNKNOWN","sponsor":"Peking Union Medical College Hospital","startDate":"2023-04-01","conditions":["Pheochromocytoma, Metastatic","Pheochromocytoma Malignant","Paraganglioma, Malignant"],"enrollment":5,"completionDate":"2025-03-01"},{"nctId":"NCT05862337","phase":"PHASE3","title":"Anlotinib Hydrochloride Capsules Combined With Penpulimab Injection for the Treatment of Hepatocellular Carcinoma at High Risk of Recurrence.","status":"RECRUITING","sponsor":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","startDate":"2023-05-10","conditions":["Hepatocellular Carcinoma"],"enrollment":480,"completionDate":"2026-12"},{"nctId":"NCT05809336","phase":"PHASE2,PHASE3","title":"Gut Microbial Metabolites Inosine Combined With PD-1/PD-L1 Inhibitor for Patients With Malignant Advanced Solid Tumors","status":"COMPLETED","sponsor":"Beijing Friendship Hospital","startDate":"2019-05-01","conditions":["Advanced Solid Tumor"],"enrollment":172,"completionDate":"2022-10-31"},{"nctId":"NCT05800080","phase":"NA","title":"An Exploratory Study of Immunotherapy Combined With Anlotinib and Chemotherapy in Perioperative Treatment of LAGC","status":"UNKNOWN","sponsor":"Xijing Hospital","startDate":"2023-04","conditions":["Gastric Cancer"],"enrollment":114,"completionDate":"2025-02"},{"nctId":"NCT05784987","phase":"NA","title":"R-MINE+X in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma","status":"UNKNOWN","sponsor":"The First Affiliated Hospital with Nanjing Medical University","startDate":"2023-04-15","conditions":["Diffuse Large B-cell Lymphoma"],"enrollment":60,"completionDate":"2025-01-01"},{"nctId":"NCT05400876","phase":"PHASE1,PHASE2","title":"To Evaluate the Safety and Efficacy of TQB2618 Injection Combined With Penpulimab in the Treatment of Patients With Relapsed and Refractory Lymphoma","status":"UNKNOWN","sponsor":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","startDate":"2022-06-09","conditions":["Relapsed/Refractory Lymphoma"],"enrollment":92,"completionDate":"2023-10"},{"nctId":"NCT05726175","phase":"PHASE2","title":"Disitamab Vedotin(RC48) Combined With Penpulimab(AK105) for Neoadjuvant Treatment of HER2-low Breast Cancer","status":"UNKNOWN","sponsor":"West China Hospital","startDate":"2023-03-01","conditions":["Breast Cancer"],"enrollment":20,"completionDate":"2024-08-31"},{"nctId":"NCT05680038","phase":"","title":"Penpulimab in Maintenance Therapy in Lymphoma","status":"UNKNOWN","sponsor":"WEI XU","startDate":"2023-03-01","conditions":["Lymphoma"],"enrollment":167,"completionDate":"2025-03"},{"nctId":"NCT05332821","phase":"","title":"TACE in Combination With PD-1/PD-L1 Inhibitors and Molecular Target Therapies for Advanced HCC","status":"UNKNOWN","sponsor":"Zhongda Hospital","startDate":"2022-12-28","conditions":["Hepatocellular Carcinoma"],"enrollment":474,"completionDate":"2023-08-31"},{"nctId":"NCT05332496","phase":"","title":"TACE in Combination With PD-1/PD-L1 Inhibitors and Molecular Target Therapies for Intermediate HCC","status":"UNKNOWN","sponsor":"Zhongda Hospital","startDate":"2022-12-28","conditions":["Hepatocellular Carcinoma"],"enrollment":220,"completionDate":"2023-09-30"},{"nctId":"NCT05344924","phase":"PHASE2,PHASE3","title":"TACE Combined With Penpulimab and Anlotinib for Advanced HCC","status":"UNKNOWN","sponsor":"Zhongda Hospital","startDate":"2022-10-12","conditions":["Hepatocellular Carcinoma"],"enrollment":109,"completionDate":"2024-03-31"},{"nctId":"NCT05563480","phase":"PHASE2","title":"TQB2618 Injection Combined With Penpulimab Injection in the Treatment of Patients With Recurrent/Metastatic Nasopharyngeal Carcinoma","status":"UNKNOWN","sponsor":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","startDate":"2022-10-27","conditions":["Nasopharyngeal Carcinoma"],"enrollment":90,"completionDate":"2024-05"},{"nctId":"NCT05561699","phase":"NA","title":"Sequential Preoperative Penpulimab Combined With Chemoradiotherapy(CRT) for Locally Advanced Esophageal Squamous Cell Cancer","status":"UNKNOWN","sponsor":"Shanghai Zhongshan Hospital","startDate":"2022-09-28","conditions":["Esophageal Squamous Cell Carcinoma"],"enrollment":66,"completionDate":"2024-12-31"},{"nctId":"NCT05519202","phase":"PHASE2","title":"Exploratory Clinical Study of Penpulimab Combined With SOX in the Perioperative Treatment of Gastric Cancer","status":"UNKNOWN","sponsor":"The Central Hospital of Lishui City","startDate":"2022-08-31","conditions":["Gastric Cancer"],"enrollment":47,"completionDate":"2024-08-31"},{"nctId":"NCT05488353","phase":"PHASE4","title":"A Clinical Study of Disitamab Vedotin for Injection Combined With Penpulimab Injection in Neoadjuvant Therapy for Patients With HER2-expressing Cisplatin-intolerant cT2-T4aNxM0 Bladder Urothelial Carcinoma","status":"NOT_YET_RECRUITING","sponsor":"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","startDate":"2022-09-01","conditions":["Bladder Cancer"],"enrollment":48,"completionDate":"2026-04-30"},{"nctId":"NCT05485350","phase":"PHASE2","title":"Anlotinib , Penpulimab Combined With SBRT for Metastatic Non-Small Cell Lung Cancer (NSCLC)","status":"UNKNOWN","sponsor":"Peking University Third Hospital","startDate":"2022-09-12","conditions":["Non-Small Cell Lung Cancer"],"enrollment":32,"completionDate":"2024-10-15"},{"nctId":"NCT05460481","phase":"PHASE2","title":"Anlotinib Plus Penpulimab in Advanced Non-Small-Cell Lung Cancer Previously Treated With PD-1/PD-L1 Inhibitors","status":"UNKNOWN","sponsor":"Hunan Cancer Hospital","startDate":"2022-06-12","conditions":["Non Small Cell Lung Cancer"],"enrollment":29,"completionDate":"2024-12"},{"nctId":"NCT05244993","phase":"PHASE2","title":"AK105 Plus Anlotinib Hydrochloride Combined With Albumin Paclitaxel as a First-line Therapy in Patients With Advanced Triple-negative Breast Cancer","status":"UNKNOWN","sponsor":"Liaoning Cancer Hospital & Institute","startDate":"2022-07","conditions":["Breast Neoplasm Female"],"enrollment":42,"completionDate":"2024-03"},{"nctId":"NCT05387109","phase":"PHASE4","title":"Penpulimab Combined With Anlotinib in Neoadjuvant Treatment of Resectable Non-small Cell Lung Cancer","status":"UNKNOWN","sponsor":"Tang-Du Hospital","startDate":"2022-06-30","conditions":["NSCLC"],"enrollment":41,"completionDate":"2024-04-20"},{"nctId":"NCT05385900","phase":"NA","title":"Immune Combined Targeted and Chemotherapy in Perioperative Treatment of Locally Advanced Gastric Cancer","status":"UNKNOWN","sponsor":"Xijing Hospital","startDate":"2022-06-30","conditions":["Gastric Cancer"],"enrollment":57,"completionDate":"2024-06-30"},{"nctId":"NCT05319886","phase":"","title":"Observational Study of the Efficacy and Safety of Anlotinib Combined With Penpulimab in Elderly Lung Cancer Patients","status":"UNKNOWN","sponsor":"The First Affiliated Hospital of Xinxiang Medical College","startDate":"2022-05-16","conditions":["Lung Cancer","Lung Carcinoma","Non Small Cell Lung Cancer","Non-small Cell Carcinoma","Lung Neoplasm"],"enrollment":40,"completionDate":"2025-03-30"},{"nctId":"NCT05347641","phase":"PHASE2","title":"Penpulimab Combined With RMA Treatment of Primary Diagnosis of Primary Central Nervous System Lymphoma","status":"NOT_YET_RECRUITING","sponsor":"The First Affiliated Hospital with Nanjing Medical University","startDate":"2022-06-01","conditions":["Primary Central Nervous System Lymphoma"],"enrollment":23,"completionDate":"2029-06-01"},{"nctId":"NCT05313906","phase":"PHASE2","title":"RC48 Plus AK105 and Cisplatin in Advanced Gastric Cancer","status":"UNKNOWN","sponsor":"Henan Cancer Hospital","startDate":"2022-05-07","conditions":["Advanced Gastric Carcinoma","HER2-positive Gastric Cancer"],"enrollment":40,"completionDate":"2024-04-30"},{"nctId":"NCT04970914","phase":"PHASE2","title":"Anlotinib Plus Penpulimab (AK105) for Chemo-refractory Metastatic Colorectal Cancer:ALTER-C003","status":"UNKNOWN","sponsor":"Peking Union Medical College Hospital","startDate":"2021-11-05","conditions":["Colorectal Cancer"],"enrollment":32,"completionDate":"2023-08-23"},{"nctId":"NCT05186558","phase":"PHASE2","title":"Penpulimab Plus R2-GemOx Regimen in Relapsed or Refractory DLBCL","status":"UNKNOWN","sponsor":"The First Affiliated Hospital with Nanjing Medical University","startDate":"2022-05-15","conditions":["Lymphoma, Large B-Cell, Diffuse","Neoplasms by Histologic Type"],"enrollment":54,"completionDate":"2026-02-15"},{"nctId":"NCT05265962","phase":"PHASE2","title":"Decitabine Plus Penpulimab as Second-line Therapy for Advanced ESCC Treated With PD-1 Blockade","status":"UNKNOWN","sponsor":"The First Affiliated Hospital of Zhengzhou University","startDate":"2022-12-01","conditions":["Esophageal Squamous Cell Carcinoma"],"enrollment":85,"completionDate":"2024-12-31"},{"nctId":"NCT05244642","phase":"PHASE3","title":"A Phase III Study to Evaluate the Efficacy and Safety of Penpulimab in the Relapsed and Refractory Classical Hodgkin's Lymphoma","status":"RECRUITING","sponsor":"Akeso","startDate":"2022-02-15","conditions":["Hodgkin Disease Lymphoma"],"enrollment":60,"completionDate":"2026-03-30"},{"nctId":"NCT04952493","phase":"PHASE2","title":"Anlotinib or Penpulimab in Combination With RAI for DTC","status":"UNKNOWN","sponsor":"Peking Union Medical College Hospital","startDate":"2021-09-15","conditions":["Thyroid Cancer"],"enrollment":42,"completionDate":"2024-07-20"},{"nctId":"NCT05137171","phase":"PHASE2","title":"AK105 Combined With Anlotinib in Patients With Cervical Cancer","status":"UNKNOWN","sponsor":"The First Affiliated Hospital of Zhengzhou University","startDate":"2022-03-01","conditions":["Cervical Cancer"],"enrollment":36,"completionDate":"2024-09-01"},{"nctId":"NCT05033587","phase":"PHASE2","title":"Study of AK105 With Anlotinib and Radiotherapy Adjuvant Therapy in MGMT Unmethylated Newly Diagnosed Glioblastoma.","status":"UNKNOWN","sponsor":"The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School","startDate":"2021-09","conditions":["MGMT-Unmethylated Glioblastoma"],"enrollment":28,"completionDate":"2023-11-01"},{"nctId":"NCT04846634","phase":"PHASE2","title":"Penpulimab-based Combination Neoadjuvant/Adjuvant Therapy for Patients With Resectable Locally Advanced Non-small Cell Lung Cancer: a Phase II Clinical Study (ALTER-L043)","status":"NOT_YET_RECRUITING","sponsor":"Tianjin Medical University Cancer Institute and Hospital","startDate":"2021-08","conditions":["Resectable Locally Advanced Non-small Cell Lung Cancer"],"enrollment":90,"completionDate":"2028-02"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"pivotalTrials":["NCT04974398","NCT03866967"],"administration":{"route":"Intravenous","formulation":"Injectable","formulations":[{"form":"INJECTABLE","route":"INTRAVENOUS","productName":""}]},"crossReferences":{"UNII":"IBS1BZ4E4I","RXCUI":"2712652","SPL_ID":"3392cd59-0d45-e081-e063-6394a90a0353","chemblId":"CHEMBL4297571"},"formularyStatus":[],"_enricherVersion":"v2-openfda","developmentCodes":[],"ownershipHistory":[{"period":"2025-","companyName":"Akeso Biopharma","relationship":"Original Developer"}],"pharmacokinetics":{"source":"OpenFDA Label","halfLife":"32 days"},"publicationCount":62,"therapeuticAreas":["Oncology"],"applicationNumber":"BLA761258","biosimilarFilings":[],"originalDeveloper":"Akeso Biopharma","recentPublications":[{"date":"2026 Mar 20","pmid":"41860583","title":"Cost-effectiveness of first-line immune checkpoint inhibitor therapies, alone or combined with targeted agents, for unresectable hepatocellular carcinoma in China: an economic evaluation using network meta-analysis.","journal":"Immunotherapy"},{"date":"2026 Mar 19","pmid":"41854985","title":"Cost-Effectiveness Analysis of Anlotinib Plus Penpulimab Versus Sorafenib in the First-Line Treatment of Unresectable Hepatocellular Carcinoma in China.","journal":"Clinical drug investigation"},{"date":"2026 Feb 28","pmid":"41816591","title":"Anlotinib and penpulimab in advanced hepatocellular carcinoma: a new contender emerges.","journal":"Journal of gastrointestinal oncology"},{"date":"2026","pmid":"41804358","title":"Immune checkpoint inhibitor-based first-line therapies for advanced or unresectable hepatocellular carcinoma: a network meta-analysis and cost-effectiveness analysis.","journal":"Therapeutic advances in medical oncology"},{"date":"2026","pmid":"41694404","title":"Efficacy and safety of first-line immunotherapy and targeted therapy in advanced HCC: a network meta-analysis with subgroup analysis based on HBV and HCV infection.","journal":"Frontiers in immunology"}],"companionDiagnostics":[],"genericManufacturerList":[],"status":"active","companyName":"Akeso Biopharma","companyId":"akeso-biopharma","modality":"Monoclonal antibody","firstApprovalDate":"2025","aiSummary":"","enrichmentLevel":3,"visitCount":1,"regulatoryByCountry":[{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2025-04-23T00:00:00.000Z","mah":"AKESO BIOPHARMA","brand_name_local":null,"application_number":"BLA761258"},{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":"AKESO BIOPHARMA","brand_name_local":null,"application_number":""},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":3,"withResults":0},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T00:51:00.812171+00:00","fieldsConflicting":0,"overallConfidence":0.95},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}